



(51) International Patent Classification:

C07D 261/04 (2006.01)

A01N 43/80 (2006.01)

C07D 413/12 (2006.01)

(21) International Application Number:

PCT/EP2022/066422

(22) International Filing Date:

15 June 2022 (15.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/211,478

16 June 2021 (16.06.2021)

US

(71) Applicants: ELANCO TIERGESUNDHEIT AG

[CH/US]; c/o Elanco Animal Health, 2500 Innovation Way, Greenfield, Indiana 46140 (US). BAYER ANIMAL HEALTH GMBH [DE/US]; c/o Elanco Animal Health, 2500 Innovation Way, Greenfield, Indiana 46140 (US).

(72) Inventors: DUCRAY, Pierre; c/o Elanco Animal Health,

2500 Innovation Way, Greenfield, Indiana 46140 (US). RA-GEOT, Denise; c/o Elanco Animal Health, 2500 Innovation Way, Greenfield, Indiana 46140 (US). TURBERG, Andreas; c/o Elanco Animal Health, 2500 Innovation Way, Greenfield, Indiana 46140 (US).

(74) Agent: COHAUSZ & FLORACK PATENT- UND

RECHTSANWÄLTE PARTNERSCHAFTSGESELLSCHAFT MBB; Bleichstraße 14, 40211 Düsseldorf (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ISOXAZOLINE PESTICIDES



(I)

(57) Abstract: The present invention provides compounds of formula (I) which are useful for long-lasting treatment and control of pests, for example fleas and ticks, in companion animals and livestock, and pharmaceutical compositions and methods of using the same.



ISOXAZOLINE PESTICIDES

FIELD

5 The present invention relates to medicinal chemistry, pharmacology, and veterinary and human medicine.

BACKGROUND

10 The aryl isoxazolines are used in agriculture, forestry, turf, household, wood products, nursery crops protection, and veterinary fields. The veterinary field includes companion animals and livestock, including fish. For example, such inhibitors are disclosed in WO 2005/085216, WO 2007/079162, US 2007/066617, US20130131017, WO 2009/002809, WO 2009/112275, WO 2010/003923, WO 2010/070068, WO 2012/120399, WO 2013/079407, and WO 2021/127188.


15 In many applications, long lasting effect against pests is desirable. Long lasting protection is particularly important with companion animals, such as dogs and cats and also mice, guinea pigs, ferrets, and rabbits; and with ranched animals such as cattle, sheep, pigs, and fish, in particular salmon and sea bass.

SUMMARY

20 The present invention relates to a compound of formula (I) having extended half-life in companion animals and livestock, in particular, warm-blooded animals, especially dogs, cats and cattle, and their use in the control of ectoparasites. In many cases the compound of formula (I) provides long duration of action for months after a single oral
25 administration or an injection.

The present invention also provides compounds of formula (I) which effectively treat and/or control ectoparasites in companion animals and livestock.

30 In one embodiment, the present invention provides a compound of formula (I):



wherein

A₁ is selected from the group consisting of CF₃, CHF₂, CH₂F, and CF₂CF₃;

A₂ is O or S;

5 R₁ is selected from the group consisting of hydrogen and halogen;

R₂ is selected from the group consisting of hydrogen, halogen, difluoromethyl, and trifluoromethyl;

R₃ is selected from the group consisting of hydrogen, halogen, and trifluoromethyl;

10 R₄ is selected from the group consisting of hydrogen, halogen, difluoromethyl, and trifluoromethyl;

R₅ is selected from the group consisting of hydrogen and halogen;

provided that:

15 R₁ may be hydrogen only when R₂ is trifluoromethyl, difluoromethyl, or bromo;

R₅ may be hydrogen only when R₄ is trifluoromethyl or bromo;


R₃ may be hydrogen only when one of R₂ or R₄ is either trifluoromethyl, difluoromethyl, or bromo;

R₁, R₃, and R₅ cannot all be hydrogen when R₂ and R₄ are trifluoromethyl;

20 and

at most three of R₁, R₂, R₃, R₄, and R₅ are hydrogen;

Q is selected from the group consisting of



wherein

p is 0, 1, or 2;

q is 0, 1, 2, or 3;

5 r is 0 or 1;

s is 0, 1, or 2;

t is 0 or 1;

R₆, at each occurrence, is independently selected from the group consisting of halogen; cyano; nitro; hydroxyl; -NH₂; -NH(C₁-C₄ alkyl); -N(C₁-C₄ alkyl)₂; C₂-C₅-alkoxycarbonyl; C₁-C₆-alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl; C₁-C₆-alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of

10 halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇

15

aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl; -NR₈C(O)(C₁-C₄ alkyl) optionally substituted on the C₁-C₄ alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂, wherein R₈ is independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; -C(O)NR₈(C₁-C₄ alkyl) optionally substituted on the C₁-C₄ alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂, wherein R₈ is independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; -SC₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂; and -S(O)C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂;

R₇, at each occurrence, is independently selected from the group consisting of oxo, C₁-C₄ alkyl, and C₃-C₆ cycloalkyl;

A₃ is O or S;

20 A₄ is CH or N;

A₅ is CH or N;

A₆ is CH or N;

A₇ is CH O, S, a bond, or N;

A₈ is CH O, S, a bond, or N;

25 A₉ is CH or N;

A₁₀ is CH or N;

A₁₁ is CH or N;

A₁₂ is CH or N;

A₁₃ is CH or N;

30 A₁₄ is CH or N;

A₁₅ is CH or N;

A₁₆ is NR, O, or S, wherein R is selected from the group consisting of hydrogen, C₁-C₄ alkyl, and C₃-C₆ cycloalkyl;

W₁ is selected from the group consisting of -O-, -S-, -NR₉-, -NC(O)R₁₀-, -CH₂-, and -C(O)-;

5 W₂ is selected from the group consisting of -O-, -S-, -NR₉-, -NC(O)R₁₀-, -CH₂-, and -C(O)-;

provided that:

when W₁ is -O-, -S-, -NR₉-, or -NC(O)R₁₀- then W₂ is -CH₂- or -C(O)-;
and

10 when W₂ is -O-, -S-, -NR₉-, or -NC(O)R₁₀- then W₁ is -CH₂- or -C(O)-;

W₃ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

W₄ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

15 W₅ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

W₆ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

wherein the bonds between W₁, W₂, W₃, and W₄ may be single or double bonds;

20 provided that:

- (i) not more than two of W₁, W₂, W₃, and W₄ are nil;
- (ii) not more than two of W₁, W₂, W₃, and W₄ are -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, or -C(O)-;
- (iii) if two of W₁, W₂, W₃, and W₄ are -O- and/or -S- then at least one
25 carbon atom is present between them; and
- (iv) when W₁, W₂, W₃, or W₄ is -CH- and/or -NR₉- then a double bond is
formed within the ring formed by W₁, W₂, W₃, and W₄;

R₉, at each occurrence, is independently selected from the group consisting of hydrogen and C₁-C₆-alkyl optionally substituted with 1 to 5 substituents independently
30 selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl;

R₁₀, at each occurrence, is independently selected from the group consisting of oxo, C₁-C₄ alkyl, and C₃-C₆ cycloalkyl;


X is 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N,

5 wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇
 10 aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl,

15 wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, and C₃-C₆ cycloalkyl;

or

X is selected from the group consisting of



25 wherein

R₁₁ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₂-C₇ alkylcarbonyl, C₂-C₅ alkoxy carbonyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl;

W is selected from the group consisting of

(i) hydrogen;

(ii) C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently

- 5 selected from the group consisting of halogen; cyano; hydroxyl; oxo; C₁-C₄ alkoxy; C₃-C₆ cycloalkyl optionally substituted by 1 to 3 substituents independently selected from the group halogen and cyano; acetylenyl; -NH₂; C₁-C₇ aminocarbonyl; -NH(C₁-C₄ alkyl); -N(C₁-C₄ alkyl)₂; -SC₁-C₄ alkyl; -S(O)C₁-C₄ alkyl; -SO₂C₁-C₄ alkyl; -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, and -NH₂; -C(O)NH-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, and -NH₂; -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen; -C(O)NH-C₁-C₆ haloalkyl; -C(O)-4- to 7-membered heterocycloalkyl attached by a nitrogen and optionally having 1 or 2 other heteroatoms selected from the group O, S, and N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH₂, C₁-C₇ aminocarbonyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any other N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl; 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are

optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any S in the heteroaryl is optionally substituted with 1 or 2 oxygen atom(s); phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl; C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C₁-C₄ haloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl; and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, B, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, wherein any B in the of the 4- to 7-membered

heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with hydroxyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of

- 5 hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, -C(O)-NH₂, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, 5- to 10 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s);

- 15 (iii) C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, carboxyl, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C₁-C₄ haloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, C₂-C₆ alkenyl optionally substituted with 1 to 3 halogens, and C₂-C₆ alkynyl;

- (iv) 6-membered aryl or 5- to 10-membered heteroaryl having 1, 2 or 3 heteroatoms selected from the group O, S, and N, wherein the carbons of the 6-membered aryl and the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 25 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ 30 cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen,

and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl;

- 5 (v) 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, -C(O)-NH₂, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s); and

(vi) -NR₁₂R₁₃

wherein

- R₁₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₁-C₇ alkylcarbonyl, C₁-C₇ aminocarbonyl, and C₂-C₅ alkoxycarbonyl;

R_{13} is selected from the group consisting of hydrogen, C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and
 5 -SO₂C₁-C₄ alkyl, C₃-C₆ cycloalkyl, -C(O)-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl, 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected
 10 from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the
 15 group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, and C₃-C₆ cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency
 20 permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆
 25 cycloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s); and 5- to 10-membered heteroaryl having 1 or 2 heteroatoms
 30 selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally

substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

or

R₁₁ and W are taken together with the nitrogen to which they are attached to form a 4- to 7-membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S, and O, wherein the carbons of the ring are optionally substituted with 1 to 4 substituents independently selected of cyano, hydroxyl, oxo, halogen, C₁-C₂ alkoxy, N,N-di-C₁-C₄-alkylaminocarboxyl, N-C₁-C₄-alkylaminocarboxyl, C₁-C₇ aminocarboxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, cyano, hydroxyl, and C₁-C₄ alkoxy, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, hydroxyl, C₁-C₂ alkoxy, N,N-di-C₁-C₄-alkylaminocarboxyl, N-C₁-C₄-alkylaminocarboxyl, and C₁-C₇ aminocarboxyl, wherein any N in the 4- to 7-membered ring is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, C₃-

C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered ring is optionally substituted with 1 or 2 oxygen atom(s); and

Y is C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, acetylenyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)₂, -SO₂NH(C₁-C₄ haloalkyl), -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, and -NH₂, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen, -C(O)NH-C₁-C₆ haloalkyl, phenyl optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, and C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl, 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆

cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, wherein any N in the heteroaryl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents

5 independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the

10 heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano,

15 hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the

20 group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and 5- to 6-membered heteroaryl, wherein any S in the 4- to 7-

25 membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s);

or a salt thereof.

In one embodiment, the present invention also provides compositions, comprising: a

30 compound of formula (I) or a salt thereof and at least one acceptable excipient, the composition optionally further comprising at least one additional active compound.

In one embodiment, the present invention also provides a method for treating pests, comprising: administering to a subject in need thereof an effective amount of a compound of formula (I) or a salt thereof, the method optionally further comprising an effective amount of at least one additional active compound.

5

In one embodiment, the present invention also provides a method for controlling pests, comprising: administering to a subject in need thereof an effective amount of a compound of formula (I) or a salt thereof, the method optionally further comprising an effective amount of at least one additional active compound.

10

In one embodiment, the present invention also provides a method for treating or controlling pests, comprising: contacting a subject's environment with an effective amount of a compound of formula (I) or a salt thereof, the method optionally further comprising an effective amount of at least one additional active compound.

15

Thus, the invention provides for the use of the compounds of the invention as a medicament, including for the manufacture of a medicament. In one embodiment, the invention provides the manufacture of a medicament comprising a compound of formula (I) or a salt thereof for treating parasites. In one embodiment, the invention provides the manufacture of a medicament comprising a compound of formula (I) or a salt thereof for controlling pests.

20

The present invention also provides processes from making compounds of the invention and intermediates thereof.

25

DETAILED DESCRIPTION

The term "C₁-C₂ alkyl" refers to a alkyl chain having from one to two carbon atoms and includes methyl and ethyl.

30

The term "C₁-C₄ alkyl" refers to a straight or branched alkyl chain having from one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, and the like.

Likewise, the term “C₁-C₆ alkyl” refers to a straight or branched alkyl chain having from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl and the like.

- 5 The terms “C₁-C₄ haloalkyl” and “C₁-C₄ halogenoalkyl” refers to a straight or branched alkyl chain having from one to four carbon atoms and 1 to 5 halogen and includes fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, and the like.
- 10 The terms “C₁-C₆ haloalkyl” and “C₁-C₆ halogenoalkyl” refers to a straight or branched alkyl chain having from one to six carbon atoms and 1 to 5 halogen and includes fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and the like.
- 15 The term “C₂-C₆ alkenyl” refers to a straight or branched alkenyl chain having from two to four carbon atoms and one carbon-carbon double bond, and includes ethylene, propylene, iso-propylene, butylene, iso-butylene, sec-butylene, and the like.

20 The term “C₂-C₆ alkynyl” refers to a straight or branched alkynyl chain having from two to four carbon atoms and one carbon-carbon triple bond, and includes acetylene, propargyl, and the like.

25 The term “C₁-C₂ alkoxy” refers to a C₁-C₂ alkyl attached through an oxygen atom and includes methoxy and ethoxy.

30 The term “C₁-C₄ alkoxy” refers to a C₁-C₄ alkyl attached through an oxygen atom and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, and the like.

35 The term “C₁-C₆ alkoxy” refers to a C₁-C₆ alkyl attached through an oxygen atom and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, and the like.

The term “C₃-C₆ cycloalkyl” refers to an alkyl ring(s) of three to six carbon atoms, and includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. It is understood that the cycloalkyl rings can be fused, bridged, or spiro-fused.

- 5 The term “C₄-C₇ alkylcycloalkyl” refers to a C₁-C₄ alkyl substituted with a C₃-C₆ cycloalkyl such that the total number of carbons is four to seven and includes cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, and the like.

- 10 The terms “halo” “halogen” and “halo” refers to chloro, fluoro, bromo or iodo atom(s).

- The terms “4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, N, wherein the heterocycloalkyl is optionally benzo-fused” and “4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, B, N, wherein the heterocycloalkyl is optionally benzo-fused” refers to a 4- to 7-membered saturated or partially (but not fully) unsaturated ring having one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur or having one or two heteroatoms selected from the group consisting of nitrogen, oxygen, boron, and sulfur and the ring optionally includes a carbonyl to form a lactam or lactone. It is understood that where sulfur is included that the sulfur may be either -S-, -SO-, or -SO₂-. The heterocyclic ring can be monocyclic or bicyclic and any bicyclic rings can be fused, bridged, or spiro-fused. The defined 4 to 7 members are exclusive of any optional benzo fused ring. Also, as will be fully appreciated by the skilled person, the saturated or partially (but not fully) unsaturated 4- to 7-membered heterocycloalkyl ring applies to the heterocycloalkyl ring and does not apply to any benzo fused ring, which by its nature will be fully unsaturated. It is further understood that the group can be attached as a substituent by any of the ring heteroatoms, valency permitting, the carbon atoms of the heterocycloalkyl, or the carbon atoms of any benzo-fused ring. It is also understood that when an optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted on carbon, the substituents can be on the carbon atoms of the heterocycle and/or the benzo fused ring. For example, but not limiting, the term includes azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl,

thioxetanyl, dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuryl, hexahydropyrimidinyl, tetrahydropyrimidinyl, 2,6-diazaspiro[3.3]heptanyl, isoxazolidine, dihydroimidazolyl, indolyl, isoindolyl, and the like.

- 5 The term “5- or 6-membered heteroaryl” refers to a six membered, monocyclic, fully unsaturated ring with one to five carbon atoms and one or more, typically one to four, heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. For example, but not limiting, the term includes pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, and
10 the like. It is understood that a 6-membered heteroaryl can be attached as a substituent through a ring carbon or a ring nitrogen atom where such an attachment mode is available.

- Where R₁₁ and W are taken together with the nitrogen to which they are attached, the
15 term “4- to 7-membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S, and O” refers to a fully saturated or partially unsaturated (but not fully) ring having four to seven members inclusive of the nitrogen to which R₁₁ and W are attached and includes azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, dioxolanyl, tetrahydropyranyl,
20 tetrahydrothiopyranyl, tetrahydrofuryl, hexahydropyrimidinyl, tetrahydropyrimidinyl, dihydroimidazolyl, and the like.

- The term “5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N” refers to a five to ten membered, monocyclic or polycyclic fully
25 unsaturated, ring or ring system with one to nine carbon atoms and one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. For example, but not limiting, the term includes furyl, thienyl, pyrrolyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, thiazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, azepinyl, diazepinyl, benzofuryl, benzothienyl, indolyl,
30 isoindolyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzoxazolyl, benzopyrazinyl, benzopyrazolyl, quinazolyl, thienopyridyl, quinolyl, isoquinolyl, benzothiazolyl, and the like. It is understood that a 5- to 10-membered heteroaryl having


1 or 2 heteroatoms selected from the group O, S, and N can be attached as a substituent through a ring carbon or a ring nitrogen atom where such an attachment mode is available.

- 5 The term “oxo” refers to an oxygen atom doubly bonded to the carbon to which it is attached to form the carbonyl of an amide, ketone, or aldehyde. For example, a pyridone radical is contemplated as an oxo substituted 6-membered heteroaryl.

The term “carboxyl” refers to the group below:




The term “N,N-di-C₁-C₄-alkylaminocarboxyl” refers to the group immediately below:




- 15 wherein the hydrogens on the nitrogen are substituted with two independently selected C₁-C₄ alkyl groups.

Likewise, term “N-C₁-C₄-alkylaminocarboxyl” refers to the group immediately below:




- 20 wherein one of the hydrogen on the nitrogen is substituted with a C₁-C₄ alkyl group.

The term “C₂-C₅ alkoxy carbonyl” refers the group below:



wherein R is a C₁-C₄ alkyl.


The term “C₂-C₇ alkylcarbonyl” refers the group below:



5 wherein R is a C₁-C₆ alkyl.

Likewise, the term “C₂-C₇ haloalkylcarbonyl” refers to the group immediately above wherein R is an C₁-C₆ haloalkyl.

10 The term “C₁-C₇ aminocarbonyl” refers to the group below:



wherein R is a hydrogen or C₁-C₄ alkyl.

The term “nil” as used herein with reference to a group, substituent, moiety, or the like,
15 indicates that that group, substituent, or moiety is not present. Wherein a group, substituent, or moiety is ordinarily bonded to two or more other groups, substituents, or moieties, the others are bonded together in lieu of the group, substituent, or moiety which is nil. For example, with a compound having the structure A-B-C; wherein B is nil, then A is directly bonded to C and the compound is A-C. As another example, with a
20 compound having the structure A-B-C; wherein C is nil, then the compound is A-B.

The terms “salt” and “salts” refers to salts of veterinary or pharmaceutically acceptable organic acids and bases or inorganic acids and bases. Such salts are well known in the art and include those described in Journal of Pharmaceutical Science, 66, 2-19 (1977). An
25 example is the hydrochloride salt.

The term “substituted,” including when used in “optionally substituted” refers to one or more hydrogen radicals of a group being replaced with non-hydrogen radicals (substituent(s)). It is understood that the substituents may be either the same or different at every substituted position. Combinations of groups and substituents envisioned by this invention are those that are stable or chemically feasible. For compounds described herein, groups and substituents thereof may be selected in accordance with permitted valence of the atoms and the substituents, such that the selections and substitutions result in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

The term “stable” refers to compounds that are not substantially altered when subjected to conditions to allow for their production. In a non-limiting example, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for about a week.

It is understood that, where the terms defined herein mention a number of carbon atoms, that the mentioned number refers to the mentioned group and does not include any carbons that may be present in any optional substituent(s) thereon or any carbons that may be present as part of a fused ring, including a benzo-fused ring.

The skilled artisan will appreciate that certain of the compounds of the present invention exist as isomers. All stereoisomers of the compounds of the invention, including geometric isomers, enantiomers, and diastereomers, in any ratio, are contemplated to be within the scope of the present invention.

As used herein, the term “(RS)” within chemical nomenclature refers to a racemic mixture at the indicated stereocenter.

As used herein, the term “(R or S)” or “(S or R)”, within chemical nomenclature refers to one of two possible configurations at the indicated stereocenter.


The skilled artisan will also appreciate that certain of the compounds of the present invention exist as tautomers. All tautomeric forms the compounds of the invention are contemplated to be within the scope of the present invention.





- 5 Compounds of the invention also include all isotopic variations, in which at least one atom of the predominant atom mass is replaced by an atom having the same atomic number, but an atomic mass different from the predominant atomic mass. Use of isotopic variations (*e.g.*, deuterium, ^2H) may afford greater metabolic stability. Additionally, certain isotopic variations of the compounds of the invention may incorporate a
- 10 radioactive isotope (*e.g.*, tritium, ^3H , or ^{14}C), which may be useful in drug and/or substrate tissue distribution studies. Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , may be useful in Positron Emission Topography (PET) studies.


- The terms “compounds of the invention” and “a compound of the invention” and
- 15 “compounds of the present invention” and the like include the embodiment of formula (I) and the other more particular embodiments encompassed by formula (I) described herein and the exemplified compounds described herein and a salt of each of these embodiments.

The compound of formula (I) having various embodiments as follows:


- 20 formula (I):







and



5

It is understood that for A₄, A₅, A₆, A₇, A₉, A₁₀, A₁₁, A₁₂, A₁₄, and/or A₁₅ an R₆ substituent, when present, takes the place of the hydrogen of the CH.


10 It is further understood that for the compound of formula (Ig) the X group, when present, is attached at W₃, W₄, W₅, or W₆ by replacing a hydrogen of a -CH₂- or -CH- group or the R of an -NR- group.

Further embodiments of compounds of the invention are provided below:

- (1) One embodiment relates to a compound of formula (I) or a salt thereof.
- 15 (a) One embodiment relates to compounds of formula (Ia) or a salt thereof.
- (b) One embodiment relates to compounds of formula (Ib) or a salt thereof.
- (c) One embodiment relates to compounds of formula (Ic) or a salt thereof.
- (d) One embodiment relates to compounds of formula (Id) or a salt thereof.

- (e) One embodiment relates to compounds of formula (Ie) or a salt thereof.
- (f) One embodiment relates to compounds of formula (If) or a salt thereof.
- (g) One embodiment relates to compounds of formula (Ig) or a salt thereof.
- (h) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), and (g) wherein
- 5 R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is trifluoromethyl, and R₅ is halogen; or a salt thereof.
- (i) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), and (g) wherein R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is halogen, and R₅ is halogen; or a salt thereof.
- 10 (j) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), and (g) wherein R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is chloro, and R₅ is halogen; or a salt thereof.
- (k) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), and (g) wherein R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is halogen, and R₅ is chloro; or a
- 15 salt thereof.
- (l) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), and (g) wherein R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is halogen, and R₅ is fluoro; or a salt thereof.
- (m) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), and (g) wherein
- 20 R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is chloro, and R₅ is fluoro; or a salt thereof.
- (n) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), and (m) wherein A₂ is O; or a salt thereof.
- (o) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), (g), (h), (i), (j),
- 25 (k), (l), (m), and (n) wherein A₁ is CF₃; or a salt thereof.
- (p) One embodiment relates to embodiments (1), (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), and (n) wherein A₁ is CHF₂; or a salt thereof.
- (q) One embodiment relates to embodiments (1), (a), (h), (i), (j), (k), (l), (m), (n), (o), and (p) wherein A₃ is S; or a salt thereof.
- 30 (r) One embodiment relates to embodiment (q) wherein p is 1 and R₅ is C₁-C₆ alkyl; or a salt thereof.
- (s) One embodiment relates to embodiment (r) wherein R₆ is methyl; or a salt thereof.

- (t) One embodiment relates to embodiments (1), (b), (h), (i), (j), (k), (l), (m), (n), (o), and (p) wherein A_4 , A_5 , and A_6 are CH; or a salt thereof.
- (u) One embodiment relates to embodiment (t) wherein p is 1 and R_6 is C_1 - C_6 alkyl; or a salt thereof.
- 5 (v) One embodiment relates to embodiment (u) wherein R_6 is methyl; or a salt thereof.
- (w) One embodiment relates to embodiments (1), (c), (h), (i), (j), (k), (l), (m), (n), (o), and (p) wherein A_7 , A_8 , A_9 , A_{10} , A_{11} , and A_{12} are CH; or a salt thereof.
- (x) One embodiment relates to embodiments (1), (d), (h), (i), (j), (k), (l), (m), (n), (o), and (p) wherein A_{13} , A_{14} , and A_{15} are CH; or a salt thereof.
- 10 (y) One embodiment relates to embodiment (x) wherein W_1 is $-CH_2-$ and W_2 is O; or a salt thereof.
- (z) One embodiment relates to embodiments (1), (a), (b), (c), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), and (x) wherein X is



- 15 wherein R_{11} is hydrogen; or a salt thereof.
- (aa) One embodiment relates to embodiment (z) wherein W is C_1 - C_6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of
- halogen,
- cyano,
- 20 hydroxyl,
- oxo,
- C_1 - C_4 alkoxy,
- C_3 - C_6 cycloalkyl optionally substituted by 1 to 3 substituents independently selected from the group halogen and cyano,
- 25 acetylenyl,
- $-NH_2$,
- C_1 - C_7 aminocarbonyl,
- $-NH(C_1$ - C_4 alkyl),

-N(C₁-C₄ alkyl)₂,

-SC₁-C₄ alkyl,

-S(O)C₁-C₄ alkyl,

-SO₂C₁-C₄ alkyl,

5 -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents
independently selected from the group consisting of

halogen,

hydroxyl,

cyano, and

10 C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently
selected from the group consisting of

halogen,

cyano,

hydroxyl,

15 C₁-C₄ alkoxy,

C₃-C₆ cycloalkyl, and

-NH₂,

-C(O)NH-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently
selected from the group consisting of

20 halogen,

cyano,

hydroxyl,

C₁-C₄ alkoxy,

C₃-C₆ cycloalkyl, and

25 -NH₂;

-C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen,

-C(O)NH-C₁-C₆ haloalkyl,

-C(O)-4- to 7-membered heterocycloalkyl attached by a nitrogen and optionally
having 1 or 2 other heteroatoms selected from the group O, S, N, wherein the

30 carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1
to 4 substituents independently selected from the group consisting of

halogen,

- cyano,
nitro,
hydroxyl,
oxo,
5 -NH₂,
C₁-C₇ aminocarbonyl,
C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently
selected from the group consisting of
halogen,
10 cyano,
hydroxyl,
acetylenyl,
oxo,
C₁-C₄ alkoxy,
15 -NH₂,
C₁-C₇ aminocarbonyl,
-NH(C₁-C₄ alkyl),
-N(C₁-C₄ alkyl)₂,
-SC₁-C₄ alkyl,
20 -S(O)C₁-C₄ alkyl,
-SO₂C₁-C₄ alkyl,
-C(O)NH-C₃-C₆ cycloalkyl, and
-C(O)NH-C₁-C₆ alkyl, and
C₃-C₆ cycloalkyl;
25 and any other N in the 4- to 7-membered heterocycloalkyl, valency
permitting, is substituted with a substituent selected from the group
consisting of
hydrogen,
-NH₂,
30 C₁-C₇ aminocarbonyl,
-SO₂C₁-C₄ alkyl,
-SO₂C₁-C₄ haloalkyl,

C₁-C₄ alkyl optionally substituted with 1 to 5 substituents
independently selected from the group consisting of

- halogen,
- cyano,
- 5 hydroxyl,
- acetylenyl,
- C₁-C₄ alkoxy,
- NH(C₁-C₄ alkyl),
- N(C₁-C₄ alkyl)₂,
- 10 -SC₁-C₄ alkyl,
- S(O)C₁-C₄ alkyl,
- SO₂C₁-C₄ alkyl,
- C(O)NH-C₃-C₆ cycloalkyl,
- C(O)NH-C₁-C₆ alkyl,
- 15 -C(O)NH-C₁-C₆ haloalkyl;

5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group
O, S, and N and wherein the carbons of the 5- to 10-membered heteroaryl are
optionally substituted with 1, 2 or 3 substituents independently selected from the
group consisting of

- 20 halogen,
- cyano,
- nitro,
- hydroxyl,
- C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently
- 25 selected from the group consisting of
- halogen,
- cyano,
- hydroxyl,
- oxo,
- 30 C₁-C₄ alkoxy,
- NH₂,
- C₁-C₇ aminocarbonyl,

- 5 -NH(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)₂,
 -SC₁-C₄ alkyl,
 -S(O)C₁-C₄ alkyl,
 -SO₂C₁-C₄ alkyl,
 -C(O)NH-C₃-C₆ cycloalkyl,
 -C(O)NH-C₁-C₆ alkyl, and
 -C(O)NH-C₁-C₆ haloalkyl;
 10 C₃-C₆ cycloalkyl,
 C₁-C₄ haloalkyl,
 C₁-C₄ alkoxy,
 -NH₂,
 C₁-C₇ aminocarbonyl,
 -NH(C₁-C₄ alkyl),
 15 -N(C₁-C₄ alkyl)₂, and
 -C(O)NH-C₃-C₆ cycloalkyl;

and any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of

- hydrogen,
 20 C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently
 selected from the group consisting of
 halogen,
 cyano,
 hydroxyl,
 25 acetylenyl,
 oxo,
 C₃-C₆ cycloalkyl,
 C₁-C₄ alkoxy,
 -NH₂,
 30 C₁-C₇ aminocarbonyl,
 -NH(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)₂,

- 5 -SC₁-C₄ alkyl,
 -S(O)C₁-C₄ alkyl,
 -SO₂C₁-C₄ alkyl,
 -C(O)NH-C₃-C₆ cycloalkyl, and
 -C(O)NH-C₁-C₆ alkyl; and
 C₃-C₆ cycloalkyl;
and any S in the heteroaryl is substituted with 1 or 2 oxygen atom(s);
phenyl optionally substituted with 1 to 3 substituents selected from the group
consisting of
10 halogen,
 C₁-C₄ alkyl,
 cyano, or
 hydroxyl;
C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently
15 selected from the group consisting of
 halogen,
 cyano,
 hydroxyl,
 oxo,
20 C₁-C₄ alkoxy,
 C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the
 group consisting of halogen and cyano,
 C₁-C₄ haloalkyl,
 -NH₂,
25 C₁-C₇ aminocarbonyl,
 -NH(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)₂,
 -SC₁-C₄ alkyl,
 -S(O)C₁-C₄ alkyl,
30 -SO₂C₁-C₄ alkyl,
 -C(O)NH-C₃-C₆ cycloalkyl,
 -C(O)NH-C₁-C₆ alkyl,

-C(O)NH-C₁-C₆ haloalkyl,

C₂-C₆ alkenyl, and

C₂-C₆ alkynyl; and

4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, B, N, wherein the heterocycloalkyl is optionally benzo-fused, and wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of

halogen,

cyano,

nitro,

hydroxyl,

oxo,

C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of

halogen,

cyano, hydroxyl,

acetylenyl,

oxo,

C₁-C₄ alkoxy,

C₃-C₆ cycloalkyl,

-NH₂,

C₁-C₇ aminocarbonyl,

-NH(C₁-C₄ alkyl),

-N(C₁-C₄ alkyl)₂,

-SC₁-C₄ alkyl,

-S(O)C₁-C₄ alkyl,

-SO₂C₁-C₄ alkyl,

-C(O)NH-C₃-C₆ cycloalkyl,

-C(O)NH-C₁-C₆ alkyl, and

and-C(O)NH-C₁-C₆ haloalkyl;

and any B in the of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with hydroxyl,

and any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of

hydrogen,

-NH₂,

C₁-C₇ aminocarbonyl,

-SO₂C₁-C₄ alkyl,

-SO₂C₁-C₄ haloalkyl,

-C(O)-NH₂,

C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of

halogen,

cyano,

hydroxyl,

acetylenyl,

C₁-C₄ alkoxy,

-NH(C₁-C₄ alkyl),

-N(C₁-C₄ alkyl)₂,

-SC₁-C₄ alkyl,

-S(O)C₁-C₄ alkyl,

-SO₂C₁-C₄ alkyl,

-C(O)NH-C₃-C₆ cycloalkyl, and

-C(O)NH-C₁-C₆ haloalkyl;

C₃-C₆ cycloalkyl;

5- to 6-membered heteroaryl; and

phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of

halogen,

C₁-C₄ alkyl,

cyano, and

hydroxyl; and

any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is substituted with 1 or 2 oxygen atom(s);

5 or a salt thereof.

(ab) One embodiment related to embodiment (aa) wherein W is a C₁-C₆ alkyl substituted with a substituent selected from the group consisting of

-C(O)NH-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of

10 halogen,

cyano,

hydroxyl,

C₁-C₄ alkoxy,

C₃-C₆ cycloalkyl, and

15 -NH₂;

-C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen,

-C(O)NH-C₁-C₆ haloalkyl, and

-C(O)-4- to 7-membered heterocycloalkyl attached by a nitrogen and optionally having 1 or 2 other heteroatoms selected from the group O, S, N, wherein the carbons of the 4- to

20 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of

halogen,

cyano,

nitro,

25 hydroxyl,

oxo,

-NH₂,

C₁-C₇ aminocarbonyl,

C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently

30 selected from the group consisting of

halogen,


cyano,

- hydroxyl,
 acetylenyl,
 oxo,
 C₁-C₄ alkoxy,
 5 -NH₂,
 C₁-C₇ aminocarbonyl,
 -NH(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)₂,
 -SC₁-C₄ alkyl,
 10 -S(O)C₁-C₄ alkyl,
 -SO₂C₁-C₄ alkyl,
 -C(O)NH-C₃-C₆ cycloalkyl, and
 -C(O)NH-C₁-C₆ alkyl, and
 C₃-C₆ cycloalkyl;
 15 and any other N in the 4- to 7-membered heterocycloalkyl, valency
 permitting, is substituted with a substituent selected from the group
 consisting of
 hydrogen,
 -NH₂,
 20 C₁-C₇ aminocarbonyl,
 -SO₂C₁-C₄ alkyl,
 -SO₂C₁-C₄ haloalkyl,
 C₁-C₄ alkyl optionally substituted with 1 to 5 substituents
 independently selected from the group consisting of
 25 halogen,
 cyano,
 hydroxyl,
 acetylenyl,
 C₁-C₄ alkoxy,
 30 -NH(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)₂,
 -SC₁-C₄ alkyl,

- S(O)C₁-C₄ alkyl,
- SO₂C₁-C₄ alkyl,
- C(O)NH-C₃-C₆ cycloalkyl,
- C(O)NH-C₁-C₆ alkyl,
- C(O)NH-C₁-C₆ haloalkyl;

or a salt thereof.

(ac) One embodiment relates to embodiment (ab) wherein W is



10 or a salt thereof.

(ad) One embodiment relates to embodiment (z) wherein W is C₁-C₆ alkyl substituted with -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, and -NH₂; or a salt thereof.

(ae) One embodiment relates to embodiment (z) wherein W is C₁-C₆ alkyl substituted with -C(O)NH-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of

halogen,

cyano,

hydroxyl,


C₁-C₄ alkoxy,

C₃-C₆ cycloalkyl, and

-NH₂;


25 or a salt thereof.

(ae1) One embodiment relates to embodiment (ae) wherein W is



or a salt thereof.

(ae2) One embodiment relates to embodiment (ae) where in W is



5 or a salt thereof.

- (af) One embodiment relates to embodiment (z) wherein W is C₁-C₆ alkyl substituted with a 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, B, and N and wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl; C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl; and any B in the heteroaryl is substituted with hydroxyl and any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl and any S in the heteroaryl is substituted with 1 or 2 oxygen atom(s); or a salt thereof.

(af1) One embodiment relates to embodiment (z) wherein W is C₁-C₆ alkyl substituted with a pyridine optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of
5 halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl; C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl; or a salt thereof.

10 (af2) One embodiment relates to embodiment (z) wherein W is C₁-C₆ alkyl substituted with a thiazole optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of
15 halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl; C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl; or a salt thereof.

(ag) One embodiment relates to embodiment (z) wherein W is a 4- to 7-membered
20 heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, N, wherein the heterocycloalkyl is optionally benzo-fused, and wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of

25 halogen,
cyano,
nitro,
hydroxyl,
oxo,

30 C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of

halogen,

- cyano, hydroxyl,
acetylenyl,
oxo,
C₁-C₄ alkoxy,
5 C₃-C₆ cycloalkyl,
-NH₂,
C₁-C₇ aminocarbonyl,
-NH(C₁-C₄ alkyl),
-N(C₁-C₄ alkyl)₂,
10 -SC₁-C₄ alkyl,
-S(O)C₁-C₄ alkyl,
-SO₂C₁-C₄ alkyl,
-C(O)NH-C₃-C₆ cycloalkyl,
-C(O)NH-C₁-C₆ alkyl,
15 and
-C(O)NH-C₁-C₆ haloalkyl; and
and any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-
membered heterocycloalkyl, valency permitting, is substituted with a substituent selected
from the group consisting of
20 hydrogen,
-NH₂,
C₁-C₇ aminocarbonyl,
-SO₂C₁-C₄ alkyl,
-SO₂C₁-C₄ haloalkyl,
25 -C(O)-NH₂,
C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected
from the group consisting of
halogen,
cyano,
30 hydroxyl,
acetylenyl,
C₁-C₄ alkoxy,

- C₃-C₆ cycloalkyl,
-NH(C₁-C₄ alkyl),
-N(C₁-C₄ alkyl)₂,
-SC₁-C₄ alkyl,
5 -S(O)C₁-C₄ alkyl,
-SO₂C₁-C₄ alkyl,
-C(O)NH-C₃-C₆ cycloalkyl, and
-C(O)NH-C₁-C₆ haloalkyl;
C₃-C₆ cycloalkyl;
10 5- to 6-membered heteroaryl; and
phenyl optionally substituted with 1 to 3 substituents independently selected from
the group consisting of
halogen,
C₁-C₄ alkyl,
15 cyano, and
hydroxyl; and
any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-
membered heterocycloalkyl is substituted with 1 or 2 oxygen atom(s);
or a salt thereof.
- 20 (ag1) One embodiment relates to embodiment (ag) wherein W is a 4- to 7-membered
heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, N is selected
from the group consisting of pyrrolyl, azetidiny, 2-oxoazetidiny, isoxazolidiny, 2,6-
diazaspiro[3.3]heptany, and 1,6-diazaspiro[3.3]heptany wherein the carbons of the 4- to
7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents
25 independently selected from the group consisting of
halogen,
cyano,
nitro,
hydroxyl,
30 oxo,
C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected
from the group consisting of

- halogen,
cyano, hydroxyl,
acetylenyl,
oxo,
5 C₁-C₄ alkoxy,
C₃-C₆ cycloalkyl,
-NH₂,
C₁-C₇ aminocarbonyl,
-NH(C₁-C₄ alkyl),
10 -N(C₁-C₄ alkyl)₂,
-SC₁-C₄ alkyl,
-S(O)C₁-C₄ alkyl,
-SO₂C₁-C₄ alkyl,
-C(O)NH-C₃-C₆ cycloalkyl,
15 -C(O)NH-C₁-C₆ alkyl,
and
-C(O)NH-C₁-C₆ haloalkyl;
and any N in the 4- to 7-membered heterocycloalkyl 4- to 7-membered heterocycloalkyl,
valency permitting, is substituted with a substituent selected from the group consisting of
20 hydrogen,
-SO₂C₁-C₄ alkyl,
-SO₂C₁-C₄ haloalkyl,
-C(O)-NH₂,
C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected
25 from the group consisting of
halogen,
cyano,
hydroxyl,
acetylenyl,
30 C₁-C₄ alkoxy,
C₃-C₆ cycloalkyl,
-NH(C₁-C₄ alkyl),

- 5 -N(C₁-C₄ alkyl)₂,
 -SC₁-C₄ alkyl,
 -S(O)C₁-C₄ alkyl,
 -SO₂C₁-C₄ alkyl,
 -C(O)NH-C₃-C₆ cycloalkyl, and
 -C(O)NH-C₁-C₆ haloalkyl; and
 C₃-C₆ cycloalkyl;

or a salt thereof.

- 10 (ah) One embodiment relates to embodiments (ag) and (ag1) wherein the carbons of the 4- to 7-membered heterocycloalkyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of oxo and C₁-C₄ alkyl and any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by hydrogen and C₁-C₄ alkyl optionally substituted with 1 to 3 halogen, cyano, acetylenyl, or C₃-C₆ cycloalkyl; or a salt thereof.
- 15 (ai) One embodiment relates to embodiments (ag), (ag1), and (ah) wherein the carbons of the 4- to 7-membered heterocycloalkyl are substituted with 1 oxo and any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by C₁-C₄ alkyl substituted by 1 cyano; or a salt thereof.
- 20 (aj) One embodiment relates to embodiments (ag), (ag1), and (ah) wherein the carbons of the 4- to 7-membered heterocycloalkyl are substituted with 1 oxo and any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by C₁-C₄ alkyl substituted with 1 to 3 halogens; or a salt thereof.
- 25 (ak) One embodiment relates to embodiments (ag), (ag1), and (ah) wherein the carbons of the 4- to 7-membered heterocycloalkyl are substituted with 1 oxo and any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by C₁-C₄ alkyl substituted with 1 C₃-C₆ cycloalkyl; or a salt thereof.
- 30 (al) One embodiment relates to embodiments (ag), (ag1), and (ah) wherein any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by C₁-C₄ alkyl substituted with 1 cyano; or a salt thereof.
- (am) One embodiment relates to embodiments (ag), (ag1), and (ah) wherein any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by C₁-C₄ alkyl substituted with 1 to 3 halogens; or a salt thereof.

(an) One embodiment relates to embodiments (ag), (ag1), and (ah) wherein any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted by C₁-C₄ alkyl substituted with 1 C₃-C₆ cycloalkyl; or a salt thereof.

(an1) One embodiment relates to embodiment (z) wherein W is a C₃-C₆ cycloalkyl

5 optionally substituted with 1 to 5 substituents independently selected from the group consisting of

halogen,

cyano,

hydroxyl,

10 oxo,

C₁-C₄ alkoxy,

C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano,

C₁-C₄ haloalkyl,

15 -NH₂,

C₁-C₇ aminocarbonyl,

-NH(C₁-C₄ alkyl),

-N(C₁-C₄ alkyl)₂,

-SC₁-C₄ alkyl,

20 -S(O)C₁-C₄ alkyl,

-SO₂C₁-C₄ alkyl,

-C(O)NH-C₃-C₆ cycloalkyl,

-C(O)NH-C₁-C₆ alkyl,

-C(O)NH-C₁-C₆ haloalkyl,

25 C₂-C₆ alkenyl optionally substituted with 1 to 3 halogens; and

C₂-C₆ alkynyl;

or a salt thereof.


(ao) One embodiment relates to embodiments (1), (d), (e), (f), (h), (i), (j), (k), (l), (m), (n), (o), (p), (t), (x), and (y) wherein Y is C₁-C₆ alkyl optionally substituted with 1 to 5

30 substituents independently selected from the group consisting of


halogen,

cyano,


- hydroxyl,
 oxo,
 C₃-C₆ cycloalkyl,
 C₁-C₄ alkoxy,
 5 acetylenyl,
 -NH₂,
 C₁-C₇ aminocarbonyl,
 -NH(C₁-C₄ alkyl),
 -N(C₁-C₄ alkyl)₂,
 10 -SC₁-C₄ alkyl,
 -S(O)C₁-C₄ alkyl,
 -SO₂C₁-C₄ alkyl,
 -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents
 independently selected from the group consisting of
 15 halogen,
 hydroxyl,
 cyano, and
 C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently
 selected from the group consisting of
 20 halogen,
 cyano,
 hydroxyl,
 C₁-C₄ alkoxy, and
 -NH₂,
 25 -C(O)NH-C₁-C₆ alkyl,
 -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen,
 -C(O)NH-C₁-C₆ haloalkyl;
 or a salt thereof.
- (ap) One embodiment relates to embodiment (ao) wherein Y is C₁-C₆ alkyl substituted
 30 with 1 -SO₂C₁-C₄ alkyl; or a salt thereof.
- (aq) One embodiment relates to embodiment (ao) or (ap) wherein Y is C₁-C₆ alkyl
 substituted with 1 -SO₂CH₃; or a salt thereof.




(ar) One embodiment relates to embodiment (z) wherein W is




(as) One embodiment relates to embodiment (z) wherein W is




(at) One embodiment relates to embodiment (z) wherein W is




(au) One embodiment relates to embodiment (z) wherein W is



5 (as) One embodiment relates to embodiment (z) wherein W is



(at) One embodiment relates to embodiment (z) wherein W is



(au) One embodiment relates to embodiment (z) wherein W is

(xa) Another embodiment relates to each of the exemplified compounds or a salt thereof.





(xb) Another embodiment relates to each stereoisomer of each exemplified, depicted, or
5 named compound; or a salt thereof.





(xc) Another embodiment relates to a salt of each of the exemplified compounds.

The compounds of the invention can be prepared by a variety of procedures many of which are already described in the art. For example, see WO 2005/085216, WO
10 2007/079162, US 2007/066617, US20130131017, WO 2009/002809, WO 2009/112275, WO 2010/003923, WO 2010/070068, WO 2012/120399, and WO 2013/079407.

This present disclosure relates to compounds of formula (I) having extended half-lives. The compounds of formula (I) have either a trifluoromethyl group in the meta position or
15 a halogen in the para and/or ortho position(s). Thus, the compounds of formula (I) include the following features: a trifluoromethyl group at one or both meta position(s); a halogen at ortho position; a halogen at each of the ortho and the para positions; or a halogen at each of the ortho positions and a trifluoromethyl at the para position. It is understood that the compounds of formula (I) may have other substituents, but the groups
20 mentioned above are included. Without being bound to any particular theory the applicant believes that inhibition of metabolism at both of the ortho and the para position provide enhanced duration after oral administration or an injection.

The following examples are intended to be illustrative and non-limiting, and represent
25 specific embodiments of the present invention.






5

and each stereoisomer of the compounds above.

In another aspect, disclosed are compounds of formula (II), or a salt thereof,




(II)


wherein,

5 A₁ is -CF₃ or -CHF₂;

Cy₁ is selected from:





Cy₂ is selected from:




10


T₁ is selected from:








In an embodiment, disclosed are compounds of formula (IIa), or a salt thereof,



wherein A₁, Cy₁, Cy₂, and T₁ are as defined above.


In another embodiment, disclosed are compounds of formula (IIb), or a salt thereof,




wherein A₁, Cy₁, Cy₂, and T₁ are as defined above.

- 5 In certain embodiments, A₁ in formulae (II), (IIa), or (IIb) is -CF₃.


In certain embodiments, Cy₁ in formulae (II), (IIa), or (IIb) is



- 10 In certain embodiments, Cy₂ in formulae (II), (IIa), or (IIb) is



In certain embodiments, T₁ in formulae (II), (IIa), or (IIb) is




15


In certain embodiments, disclosed are compounds of formulae (II), (IIa), and (IIb), or a salt thereof, wherein

A₁ is -CF₃;

Cy₁ is selected from:




Cy₂ is




5


; and

T₁ is



10






5

In certain embodiments, disclosed are compounds of formulae (II), (IIa), and (IIb), or a salt thereof, wherein


A₁ is -CF₃;

Cy₁ is





10


Cy₂ is selected from:



T₁ is









In certain embodiments, disclosed are compounds of formulae (II), (IIa), and (IIb), or a salt thereof, wherein

A₁ is -CF₃;


Cy₁ is




Cy₂ is selected from:



T₁ is




In another aspect, disclosed are compounds of formula (III), or a salt thereof,




wherein,

A₁ is -CF₃ or -CHF₂;

Cy₃ is selected from:




Cy₄ is:




5

T₂ is selected from:




In an embodiment, disclosed are compounds of formula (IIIa), or a salt thereof,



10

wherein A₁, Cy₃, Cy₄, and T₂ are as defined above.

In another embodiment, disclosed are compounds of formula (IIIb), or a salt thereof,




15

wherein A₁, Cy₃, Cy₄, and T₂ are as defined above.


In certain embodiments, A_1 in formulae (III), (IIIa), or (IIIb) is $-CF_3$.

In certain embodiments, Cy_3 in formulae (III), (IIIa), or (IIIb) is

5




In certain embodiments, T_2 in formulae (III), (IIIa), or (IIIb) is



- 10 In certain embodiments, disclosed are compounds of formulae (III), (IIIa), and (IIIb), or a salt thereof, wherein


A_1 is $-CF_3$;

Cy_3 is




15

Cy_4 is selected from:



; and

T_3 is



- 20 The following examples are intended to be illustrative and non-limiting, and represent specific embodiments of the present invention.

Analyses were performed using a Waters Acquity UPLC Liquid Chromatography (LC) system, coupled to a Waters SQ Detector 2 single quadrupole mass spectrometry (MS) detector. The UV (DAD) acquisition was performed with a scan range of 200-400 nm (by 1.2nm resolution). The MS was operated with an electro-spray ionization source (ESI) in
5 both positive and negative ion mode. Capillary Voltage 3.50 (kV), Cone Voltage 35 (V), and Desolvation Temperature of 550 °C. Desolvation gas flow 1000 (L/Hr), Cone gas flow 50 (L/Hr). The MS acquisition range was set to 100-1500 m/z . MS scan cycle time was 0.5 s. Data acquisition was performed with Waters Masslynx software.

10 Method A: Analyses were carried out on an Acquity UPLC BEH C18 column of 50 mm length, 2.1 mm internal diameter and 1.7 μ m particle size. The mobile phase used was: A= water with 0.1% formic acid / B= CH₃CN with 0.1% formic acid.

Method B: Analyses were carried out on an Acquity UPLC BEH C18 column of 50 mm
15 length, 2.1 mm internal diameter and 1.7 μ m particle size. The mobile phase used was: A= water with 0.1% formic acid / B= CH₃CN.

Method C: Analyses were carried out on an Acquity UPLC BEH C18 column of 50 mm
20 length, 2.1 mm internal diameter and 1.7 μ m particle size. The mobile phase used was: A= water with 10 mM ammonium acetate / B= CH₃CN.

Analysis were performed using an Ultra High Performance Liquid Chromatography (UHPLC) system (Make- Thermo Scientific), coupled with an Ion trap mass analyzer. The UV acquisition was performed with a scan range of 200-400 nm (by 1nm resolution). The
25 MS was operated with an electro-spray ionization source (ESI) in both positive & negative ion mode, with sheath gas flow rate(arb): 40, Aux gas flow rate (arb): 20, sweep gas flow rate(arb): 1, spray voltage (kv): 5, capillary temp (°C): 350 ,capillary voltage (V):30 ,tube lens (V): positive mode 30 and negative mode -30. The MS acquisition range was set to 100-2000 m/z . MS scan cycle time was 3 micro scans. Data acquisition was performed with
30 Xcalibur software.

Method D: Analyses were carried out on Ascentis Express C18 of 5cm length, 2.1 mm internal diameter and 2.7µm particle size. The mobile phase used was: A= water with 0.1% formic acid / B= 100% CH₃CN.

- 5 Analyses were performed using a Liquid Chromatography (LC) system, coupled to a quadrupole mass spectrometry (MS) detector. The UV (DAD) acquisition was performed with a scan range of 200-400 nm.

LC-MS, Analytical Method E:

- 10 Instrument: SHIMADZU LCMS - UFLC 20-AD - LCMS 2020 MS detector; Column: Ascentis Express C18 2.7 µm, 50 x 3.0 mm; eluent A: water + 0.05 vol % trifluoroacetic acid, eluent B: CH₃CN + 0.05 vol % trifluoroacetic acid.

LC-MS, Analytical Method F:

- 15 Instrument: SHIMADZU LCMS - UFLC 20-AD - LCMS 2020 MS detector; Column: Kinetex EVO C18 2.6 µm, 50 x 3.0 mm; eluent A: water + 0.05 vol % ammonium hydrogencarbonate, eluent B: CH₃CN.

- As used herein: aq. refers to aqueous, br refers to broad, CH₃CN refers to acetonitrile, d
20 refers to doublet, dd refers to doublet of doublet, DCM refers to dichloromethane, DCE refers to dichloroethane, DIPEA refers to N-diisopropylethylamine, DMF refers to N,N-dimethylformamide, DMSO refers to dimethylsulfoxide, ee: refers to enantiomeric excess, ES refers to electrospray ionization, EtOAc refers to ethyl acetate, h refers to hour(s), HATU refers to 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-
25 oxid hexafluorophosphate, HPLC refers to high performance liquid chromatography, iPrOH refers to isopropanol, J refers to coupling constant, LCMS refers to liquid chromatography – mass spectrometry, *m/z*: refers to mass-to-charge ratio, M refers to molarity, m refers to multiplet, MeOH refers to methanol, min refers to minutes, NaHCO₃ refers to sodium bicarbonate, Na₂CO₃ refers to sodium carbonate, NEt₃ refers to
30 triethylamine, NMR refers to nuclear magnetic resonance, q refers to quartet, quint refers to quintet, rt refers to room temperature, R_t refers to retention time, s refers to singlet, sat.

refers to saturated, T refers to temperature, t refers to triplet, td refers to triplet of doublets, THF refers to tetrahydrofuran, wt refers to weight, and δ refers to chemical shift.


4-((*R*^{*})-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((*S*)-1-ethyl-5-oxopyrrolidin-3-yl)-2-methylbenzamide

(Example 1.1)

and

5 4-((*S*^{*})-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((*S*)-1-ethyl-5-oxopyrrolidin-3-yl)-2-methylbenzamide

(Example 1.2)



To a stirred solution of 2-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.3 g, 3.5 mmol) in THF (15 mL) and water (7.5 mL) was added dipotassium carbonate (1.02 g, 7.38 mmol) and the mixture was degassed with N₂-gas for 10 min. 2-Bromo-3,3,3-trifluoro-prop-1-ene (0.76 g, 4.3 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.25 g, 0.36 mmol) were added and the reaction mixture was heated at 80°C for 3 h. Then, the mixture was allowed to cool to rt and was extracted with diethyl ether (2x10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 1-bromo-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene as brown liquid, which was immediately used in the next step without further purification.

To a stirred solution of methyl 4-(hydroxyiminomethyl)-2-methyl-benzoate (500 mg, 2.59 mmol) in DMF (5 mL) was added N-chlorosuccinimide (0.45 g, 3.4 mmol) at rt and the mixture was heated at 40°C for 10 min. Then, the mixture was cooled to 0°C and 1-bromo-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene (1.05 g, 3.12 mmol) was added followed by NEt₃ (0.40 mL, 2.85 mmol) and the reaction was stirred at rt for 3 h. The reaction mixture was quenched by adding water (10 mL) and extracted with EtOAc (30 mL). The organic layer was washed with brine (3x 15 mL), dried over




anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (0-20% EtOAc in petroleum ether) to afford methyl 4-[5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoate as beige semisolid. LC-MS (method A) R_t= 2.78 min,
5 m/z = 528.1 [M+H]⁺.






To a stirred solution of methyl 4-[5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoate (500 mg, 0.9 mmol) in THF (5 mL) and water (5 mL) was added lithiumhydroxide monohydrate (0.12 g, 2.9 mmol) at rt and
10 the mixture was heated at 60°C for 16 h. Then, the mixture was allowed to cool to rt and the solvent was evaporated under reduced pressure. The residue was dissolved in water (5 mL), acidified to pH ~2-3 with an HCl solution (1M) and extracted with EtOAc (2x 25 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 4-[5-[3-bromo-2-fluoro-5-
15 (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid as a beige solid. LC-MS (method D) R_t= 2.74 min, m/z = 514.3 [M+H]⁺.




To a stirred solution of 4-[5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid (0.31 g, 0.60 mmol) and (S)-4-
20 amino-1-ethylpyrrolidin-2-one·HCl (121 mg, 0.73 mmol) in DMF (5 mL) was added HATU (0.28 g, 0.74 mmol) followed by DIPEA (0.32 mL, 1.8 mmol) at rt and the mixture was stirred for 2 h. The reaction mixture was quenched by adding water (5 mL) and was extracted with EtOAc (3x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product
25 was purified by column chromatography on silica gel (0-50% EtOAc in petroleum ether) to afford the title compound. LC-MS (method B) R_t= 2.26 min, m/z = 624.1 [M+H]⁺. ¹H NMR (DMSO-d₆, 400 MHz) δ 8.77 (d, J = 6.8 Hz, 1 H), 8.45-8.40 (m, 1 H), 7.96-7.91 (m, 1 H), 7.68-7.61 (m, 2 H), 7.42 (d, J = 8.0 Hz, 1 H), 4.55 (d, J = 18 Hz, 1 H), 4.53-4.47 (m, 1 H), 4.38 (d, J = 18 Hz, 1 H), 3.72 (dd, J = 10, 7.2 Hz, 1 H), 3.29-3.17 (m, 3 H), 2.68-2.61
30 (m, 1 H), 2.37 (s, 3 H), 2.34-2.25 (m, 1 H), 1.03 (t, J = 7.2 Hz, 3 H).






The two enantiomers were separated by SFC. The separation was performed on Chiralcel-OJ-H with column dimensions of 250 mm × 30 mm (5 μm), a flow rate of 95.0 g/min, and a CO₂-based mobile phase with 10% *i*PrOH containing 0.2% N,N-isopropylamine as additive to give Example 1.1: 4-((*R*^{*})-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((*S*)-1-ethyl-5-oxopyrrolidin-3-yl)-2-methylbenzamide and Example 1.2: 4-((*S*^{*})-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((*S*)-1-ethyl-5-oxopyrrolidin-3-yl)-2-methylbenzamide


- 10 The following compounds were prepared analogously by the methodology of Examples 1.1 and 1.2:

Ex.	Name	Structure
1.3	4-(rel-(<i>S</i>)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(<i>S</i>)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide	
1.4	4-(rel-(<i>S</i>)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(<i>R</i>)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide	
2.1	<i>cis</i> -3-(4-((<i>S</i> [*])-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzamido)cyclobutane-1-carboxylic acid	

2.2	<i>trans</i> -3-(4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzamido)cyclobutane-1-carboxylic acid	
2.3	4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(<i>cis</i> -3-(methylcarbamoyl)cyclobutyl)benzamide	
2.4	4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(<i>trans</i> -3-(methylcarbamoyl)cyclobutyl)benzamide	
3.1	rel-(S)-4-(5-(2-fluoro-3,5-bis(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)benzamide	
1.5	4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((<i>trans</i>)-3-(trifluoromethyl)cyclobutyl)benzamide	

1.6	4-(rel-(R)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(S)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide	
1.7	4-(rel-(R)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(R)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide	
1.8	4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((cis)-3-(trifluoromethyl)cyclobutyl)benzamide	

1.9	rel-4-((R)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((S*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide	
1.10	rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((S*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide	
1.11	rel-4-((R)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((R*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide	
1.12	rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((R*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide	
1.13	rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((R*)-2-(2,2,2-trifluoroethyl)isoxazolidin-4-yl)benzamide	

1.14	rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((S)-2-(2,2,2-trifluoroethyl)isoxazolidin-4-yl)benzamide	
------	--	--

5 Experimental details for compounds in the tables:

Ex.	LC-MS	¹ H NMR
1.3	LC-MS (method B) R _t = 2.37 min, <i>m/z</i> = 662.3 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.90 (d, J = 6.0 Hz, 1 H), 8.45-8.41 (m, 1 H), 7.96-7.91 (m, 1 H), 7.69-7.62 (m, 2 H), 7.46 (d, J = 8.0 Hz, 1 H), 4.95-4.86 (m, 1 H), 4.56 (d, J = 18 Hz, 1 H), 4.42-4.30 (m, 2 H), 4.08-4.00 (m, 2 H), 3.46 (dd, J = 12, 4.8 Hz, 1 H), 3.20 (s, 3 H), 2.38 (s, 3 H).
1.4	LC-MS (method B) R _t = 2.37 min, <i>m/z</i> = 662.3 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.90 (d, J = 6.0 Hz, 1 H), 8.45-8.41 (m, 1 H), 7.95-7.91 (m, 1 H), 7.69-7.62 (m, 2 H), 7.46 (d, J = 8.0 Hz, 1 H), 4.94-4.86 (m, 1 H), 4.56 (d, J = 18 Hz, 1 H), 4.42-4.30 (m, 2 H), 4.08-4.00 (m, 2 H), 3.46 (dd, J = 12, 4.8 Hz, 1 H), 3.20 (s, 3 H), 2.38 (s, 3 H).
1.5	LC-MS (method C) R _t = 2.63 min, <i>m/z</i> = 591.1 [M+H] ⁺	¹ H NMR (400 MHz, DMSO-d ₆): δ 8.78 (d, J = 7.2 Hz, 1 H), 8.37-8.33 (d, 1 H), 7.92-7.88 (d, 1 H), 7.67-7.63 (m, 2 H), 7.44 (d, J = 7.6 Hz, 1 H), 4.61-4.35 (m, 3 H), 3.16-3.06 (m, 1 H), 2.47-2.35 (m, 7 H).
1.6	LC-MS (method B) R _t = 2.37 min, <i>m/z</i> = 662 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.90 (d, J = 6.0 Hz, 1 H), 8.45-8.41 (m, 1 H), 7.96-7.91 (m, 1 H), 7.69-7.62 (m, 2 H), 7.46 (d, J = 8.0 Hz, 1 H), 4.95-4.86 (m, 1 H), 4.56 (d, J = 18 Hz, 1 H), 4.42-4.30 (m, 2 H), 4.08-4.00 (m, 2 H), 3.46 (dd, J = 12, 4.8 Hz, 1 H), 3.20 (s, 3 H), 2.38 (s, 3 H).

1.7	LC-MS (method B) $R_t = 2.37$ min, $m/z = 662$ $[M+H]^+$	^1H NMR (DMSO- d_6 , 400 MHz) δ 8.90 (d, $J = 6.0$ Hz, 1 H), 8.45-8.41 (m, 1 H), 7.95-7.91 (m, 1 H), 7.69-7.62 (m, 2 H), 7.46 (d, $J = 8.0$ Hz, 1 H), 4.94-4.86 (m, 1 H), 4.56 (d, $J = 18$ Hz, 1 H), 4.42-4.30 (m, 2 H), 4.08-4.00 (m, 2 H), 3.46 (dd, $J = 12$, 4.8 Hz, 1 H), 3.20 (s, 3 H), 2.38 (s, 3 H).
1.8	LC-MS (method C) $R_t = 2.57$ min, $m/z = 591.0$ $[M+H]^+$	^1H NMR (400 MHz, DMSO- d_6): δ 8.74 (d, $J = 7.2$ Hz, 1 H), 8.37-8.34 (d, 1 H), 7.92-7.88 (d, 1 H), 7.67-7.62 (m, 2 H), 7.43 (d, $J = 7.6$ Hz, 1 H), 4.56 (d, $J = 18$ Hz, 1 H), 4.43-4.34 (m, 2 H), 3.01-2.87 (m, 1 H), 2.47-2.42 (m, 2 H), 2.36 (s, 3 H), 2.17-2.10 (m, 2 H).
1.9	LC-MS (method F) $R_t = 1.35$ min; $m/z = 620$ $(M+H)^+$	^1H NMR (300 MHz, DMSO- d_6) δ 9.45-9.42 (d, 1H), 8.38-8.36 (m, 1H), 7.91-7.90 (m, 1H), 7.69-7.66 (m, 2H), 7.46-7.43 (d, 1H), 6.34-6.27 (m, 1H), 4.61-4.60 (m, 1H), 4.43-4.37 (d, 1H), 3.64-3.48 (m, 2H), 3.41-3.38 (m, 1H), 2.97-4.90 (dd, 1H), 2.38 (s, 3H).
1.10	LC-MS (method F) $R_t = 1.34$ min; $m/z = 620$ $(M+H)^+$	^1H NMR (300 MHz, DMSO- d_6) δ 9.45-9.42 (d, 1H), 8.38-8.36 (m, 1H), 7.91-7.89 (m, 1H), 7.69-7.66 (m, 2H), 7.46-7.43 (d, 1H), 6.34-6.27 (m, 1H), 4.61-4.60 (m, 1H), 4.43-4.37 (d, 1H), 3.64-3.48 (m, 2H), 3.41-3.38 (m, 1H), 2.98-2.90 (m, 1H), 2.38 (s, 3H).
1.11	LC-MS (method F) $R_t = 1.35$ min; $m/z = 620$ $(M+H)^+$	^1H NMR (300 MHz, DMSO- d_6) δ 9.45-9.42 (d, 1H), 8.38-8.36 (m, 1H), 7.91-7.90 (m, 1H), 7.69-7.66 (m, 2H), 7.46-7.43 (d, 1H), 6.34-6.27 (m, 1H), 4.61-4.60 (m, 1H), 4.43-4.37 (d, 1H), 3.64-3.48 (m, 2H), 3.41-3.38 (m, 1H), 2.98-2.90 (m, 1H), 2.38 (s, 3H).
1.12	LC-MS (method F) $R_t = 1.35$ min; $m/z = 620$ $(M+H)^+$	^1H NMR (300 MHz, DMSO- d_6) δ 9.45-9.42 (d, 1H), 8.38-8.36 (m, 1H), 7.91-7.90 (m, 1H), 7.69-7.66 (m, 2H), 7.46-7.43 (d, 1H), 6.34-6.27 (m, 1H), 4.61-4.60 (d, 1H), 4.43-4.37 (d, 1H), 3.64-3.47 (m, 2H), 3.41-3.38 (m, 1H), 2.97-2.90 (m, 1H), 2.38 (s, 3H).

1.13	LC-MS (method E) R _t = 1.21 min; <i>m/z</i> = 622 (M+H) ⁺	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.67-8.65 (d, 1H), 8.38-8.37 (d, 1H), 7.91-7.90 (d, 1H), 7.70-7.68 (d, 2H), 7.49-7.46 (d, 1H), 4.85-4.77 (m, 1H), 4.61-4.60 (d, 1H), 4.54-4.37 (d, 1H), 4.22-4.12 (m, 1H), 4.10-4.00 (m, 1H), 3.73-3.72 (d, 1H), 3.28-3.23 (m, 2H), 3.19-3.04 (d, 1H), 2.49 (s, 3H).
1.14	LC-MS (method E) R _t = 1.21 min; <i>m/z</i> = 622 (M+H) ⁺	¹ H-NMR (400 MHz, DMSO-d ₆) δ 8.37-8.36 (d, 1H), 8.29-8.26 (d, 1H), 7.91-7.90 (d, 1H), 7.66-7.63 (d, 2H), 7.41-7.39 (d, 1H), 4.70-4.59 (m, 2H), 4.53-4.36 (d, 1H), 4.16-4.11 (m, 1H), 4.07-3.98 (m, 1H), 3.54-3.47 (m, 1H), 3.41-3.37 (m, 1H), 3.20-3.16 (d, 1H), 2.76-2.65 (m, 1H), 2.29-2.27 (s, 3H).
2.1	LC-MS (method C) R _t = 2.51 min, <i>m/z</i> = 567.1 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.64 (d, J = 7.2 Hz, 1 H), 8.48 (br s, 1 H), 8.37-8.34 (m, 1 H), 7.92-7.89 (m, 1 H), 7.65-7.60 (m, 2 H), 7.40 (d, J = 8.0 Hz, 1 H), 4.56 (d, J = 18 Hz, 1 H), 4.39 (d, J = 18 Hz, 1 H), 4.30-4.20 (m, 1 H), 2.69-2.61 (m, 1 H), 2.48-2.30 (m, 5 H), 2.19-2.08 (m, 2 H).
2.2	LC-MS (method B) R _t = 2.24 min, <i>m/z</i> = 567.2 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 12.2 (br s, 1 H), 8.68 (d, J = 7.6 Hz, 1 H), 8.38-8.34 (m, 1 H), 7.93-7.88 (m, 1 H), 7.68-7.61 (m, 2 H), 7.42 (d, J = 8.0 Hz, 1 H), 4.56 (d, J = 19 Hz, 1 H), 4.53-4.45 (m, 1 H), 4.40 (d, J = 18 Hz, 1 H), 3.00-2.90 (m, 1 H), 2.50-2.41 (m, 2 H), 2.36 (s, 3 H), 2.34-2.19 (m, 2 H).
2.3	LC-MS (method B) R _t = 2.20 min, <i>m/z</i> = 580.2 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.63 (d, J = 7.6 Hz, 1 H), 8.38-8.34 (m, 1 H), 7.93-7.89 (m, 1 H), 7.72-7.67 (m, 1 H), 7.66-7.59 (m, 2 H), 7.39 (d, J = 8.0 Hz, 1 H), 4.56 (d, J = 18 Hz, 1 H), 4.39 (d, J = 18 Hz, 1 H), 4.31-4.21 (m, 1 H), 2.69-2.61 (m, 1 H), 2.56 (d, J = 4.8 Hz, 3 H), 2.39-2.29 (m, 5 H), 2.19-2.08 (m, 2 H).
2.4	LC-MS (method B) R _t = 2.49 min, <i>m/z</i> = 580.1 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.62 (d, J = 7.2 Hz, 1 H), 8.38-8.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.74-7.61 (m, 3 H), 7.41 (d, J = 8.0 Hz, 1 H), 5.00-4.45 (m, 2 H), 4.40 (d, J = 18 Hz, 1 H), 2.92-2.84 (m, 1 H), 2.59 (d, J = 4.4 Hz, 3 H), 2.43-2.30 (m, 5 H), 2.24-2.14 (m, 2 H).

3.1	LC-MS (method B) R _t = 2.22 min, <i>m/z</i> = 642.4 [M+H] ⁺	¹ H NMR (DMSO-d ₆ , 400 MHz) δ 8.65-8.57 (m, 2 H), 8.43-8.39 (m, 1 H), 8.29-8.24 (m, 1 H), 7.69-7.64 (m, 2 H), 7.49 (d, J = 8.0 Hz, 1 H), 4.61 (d, J = 18 Hz, 1 H), 4.45 (d, J = 18 Hz, 1 H), 4.02-3.89 (m, 4 H), 2.40 (s, 3 H).
-----	---	---

The compounds of the invention are valuable active ingredients for use in pest control.

The term “pests” includes ectoparasites and endoparasites on and in animals and in the hygiene field. Particular pests are fleas, ticks, mites, flies, worms, and lice. Even more particular pests are fleas and ticks.

Animals in the context of the invention are understood to include vertebrates. The term vertebrate in this context is understood to comprise, for example fishes, amphibians, reptiles, birds, and mammals including humans. One preferred group of vertebrates according to the invention comprises warm-blooded animals including farm animals, such as cattle, horses, pigs, sheep and goats, poultry such as chickens, turkeys, guinea fowls and geese, fur-bearing animals such as mink, foxes, chinchillas, rabbits and the like, as well as companion animals such as ferrets, guinea pigs, rats, hamster, cats and dogs, and also humans. A further group of preferred vertebrates according to the invention comprises fishes including salmons.

In the context of the present invention, ectoparasites are understood to be in particular insects, acari (mites and ticks), and crustaceans (sea lice). These include insects of the following orders: *Lepidoptera*, *Coleoptera*, *Homoptera*, *Hemiptera*, *Heteroptera*, *Diptera*, *Dictyoptera*, *Thysanoptera*, *Orthoptera*, *Anoplura*, *Siphonaptera*, *Mallophaga*, *Thysanura*, *Isoptera*, *Psocoptera* and *Hymenoptera*. However, the ectoparasites which may be mentioned in particular are those which trouble humans or animals and carry pathogens, for example flies such as *Musca domestica*, *Musca vetustissima*, *Musca autumnalis*, *Fannia canicularis*, *Sarcophaga carnaria*, *Lucilia cuprina*, *Lucilia sericata*, *Hypoderma bovis*, *Hypoderma lineatum*, *Chrysomya chloropyga*, *Dermatobia hominis*, *Cochliomyia hominivorax*, *Gasterophilus intestinalis*, *Oestrus ovis*, biting flies such as *Haematobia irritans irritans*, *Haematobia irritans exigua*, *Stomoxys calcitrans*, horse-

- flies (*Tabanids*) with the subfamilies of *Tabanidae* such as *Haematopota* spp. (e.g. *Haematopota pluvialis*) and *Tabanus* spp, (e.g. *Tabanus nigrovittatus*) and *Chrysopsinae* such as *Chrysops* spp. (e.g. *Chrysops caecutiens*); *Hippoboscids* such as *Melophagus ovinus* (sheep ked); tsetse flies, such as *Glossinia* spp.; other biting insects like midges, such as *Ceratopogonidae* (biting midges), *Simuliidae* (Blackflies), *Psychodidae* (Sandflies); but also blood-sucking insects, for example mosquitoes, such as *Anopheles* spp, *Aedes* spp and *Culex* spp, fleas, such as *Ctenocephalides felis* and *Ctenocephalides canis* (cat and dog fleas), *Xenopsylla cheopis*, *Pulex irritans*, *Ceratophyllus gallinae*, *Dermatophilus penetrans*, blood-sucking lice (*Anoplura*) such as *Linognathus* spp, *Haematopinus* spp, *Solenopotes* spp, *Pediculus humanis*; but also chewing lice (*Mallophaga*) such as *Bovicola (Damalinia) ovis*, *Bovicola (Damalinia) bovis* and other *Bovicola* spp. . Ectoparasites also include members of the order *Acarina*, such as mites (e.g. *Chorioptes bovis*, *Cheyletiella* spp., *Dermanyssus gallinae*, *Ornithonyssus* spp., *Demodex canis*, *Sarcoptes scabiei*, *Psoroptes ovis* and *Psorergates* spp. and ticks.
- Representatives ticks are, for example, *Boophilus*, *Amblyomma*, *Anocentor*, *Dermacentor*, *Haemaphysalis*, *Hyalomma*, *Ixodes*, *Rhipicentor*, *Margaropus*, *Rhipicephalus*, *Argas*, *Otobius* and *Ornithodoros* and the like, which preferably infest vertebrates, for example warm-blooded animals including farm animals, such as cattle, horses, pigs, sheep and goats, poultry such as chickens, turkeys, guinea fowls, and geese, fur-bearing animals such as mink, foxes, chinchillas, rabbits and the like, as well as companion animals such as ferrets, guinea pigs, rats, hamster, cats and dogs, but also humans and fishes.

The compounds of the invention according to the invention are also active against all or individual development stages of animal pests showing normal sensitivity, as well as those showing resistance to widely used parasiticides. This is especially true for resistant insects and members of the order *Acarina*. The insecticidal, ovicidal and/or acaricidal effect of the active substances of the invention can manifest itself directly, i.e. killing the pests either immediately or after some time has elapsed, for example when moulting occurs, or by destroying their eggs, or indirectly, e.g. reducing the number of eggs laid and/or the hatching rate, good efficacy corresponding to a pesticidal rate (mortality) of at least 50 to 60%.

Compounds of the invention can also be used against hygiene pests, especially of the order *Diptera* of the families *Muscidae*, *Sarcophagidae*, *Anophilidae* and *Culicidae*; the orders *Orthoptera*, *Dictyoptera* (e.g. the family *Blattidae* (cockroaches), such as *Blatella germanica*, *Blatta orientalis*, *Periplaneta americana*) and *Hymenoptera* (e.g. the families

5 *Formicidae* (ants) and *Vespidae* (wasps).

The compounds of formula (I) are also effective against ectoparasites of fishes, especially the sub-class of *Copepoda* (e.g. order of *Siphonostomatoida* (sea lice), whilst being well tolerated by fish.

10

The compounds of formula (I) can also be used against worms of the class *Cestoda*, including the subclasses *Eucestoda* and *Cestodaria*.

Compounds of the invention also have sustainable efficacy on parasitic mites and insects of plants. In the case of spider mites of the order *Acarina*, they are effective against eggs,

15 nymphs and adults of *Tetranychidae* (*Tetranychus spp.* and *Panonychus spp.*).

They have high activity against sucking insects of the order *Homoptera*, especially against pests of the families *Aphididae*, *Delphacidae*, *Cicadellidae*, *Psyllidae*, *Loccidae*, *Diaspididae* and *Eriophyidae* (e.g. rust mite on citrus fruits); the orders *Hemiptera*, *Heteroptera* and *Thysanoptera*, and on the plant-eating insects of the orders *Lepidoptera*,

20 *Coleoptera*, *Diptera* and *Orthoptera*

They are similarly suitable as a soil insecticide against pests in the soil.

The compounds of formula (I) are therefore effective against all stages of development of sucking insects and eating insects on crops such as cereals, cotton, rice, maize, soya, potatoes, vegetables, fruit, tobacco, hops, citrus, avocados and other crops.

25 The compounds of formula I are also effective against plant nematodes of the species *Meloidogyne*, *Heterodera*, *Pratylenchus*, *Ditylenchus*, *Radopholus*, *Rizoglyphus* etc.

The compounds of the invention are effective against helminths. Helminths are commercially important because they cause serious diseases in mammals and poultry, e.g.

30 in sheep, pigs, goats, cattle, horses, donkeys, camels, dogs, cats, rabbits, guinea-pigs,

hamsters, chicken, turkeys, guinea fowls and other farmed birds, as well as exotic birds. Typical nematodes are: *Haemonchus*, *Trichostrongylus*, *Ostertagia*, *Nematodirus*, *Cooperia*, *Ascaris*, *Bunostomum*, *Oesophagostomum*, *Charbertia*, *Trichuris*, *Strongylus*, *Trichonema*, *Dictyocaulus*, *Capillaria*, *Heterakis*, *Toxocara*, *Ascaridia*, *Oxyuris*,
5 *Ancylostoma*, *Uncinaria*, *Toxascaris* and *Parascaris*. The trematodes include, in particular, the family of *Fasciolidae*, especially *Fasciola hepatica*.

The pesticidal activity of the compounds of formula (I) according to the invention corresponds to a mortality rate of about 50-60% of the pests mentioned, more preferably
10 to a mortality rate over 90%, most preferably to 95-100%. The compounds of formula (I) are preferably employed internally and externally in unmodified form or preferably together with the adjuvants conventionally used in the art of formulation and may therefore be processed in a known manner to give, for example, liquid formulations (e.g. spot-on, pour-on, spray-on, emulsions, suspensions, solutions, emulsifiable concentrates,
15 solution concentrates), semi-solid formulations (e.g. creams, ointments, pastes, gels, liposomal preparations) and solid preparations (e.g. food additives tablets including e. g. capsules, powders including soluble powders, granules, or embeddings of the active ingredient in polymeric substances, like implants and microparticles). As with the compositions, the methods of application are selected in accordance with the intended
20 objectives and the prevailing circumstances.

The compounds of the invention can be administered alone or in the form of a composition. In practice, the compounds of the invention are usually administered in the form of compositions, that is, in admixture with at least one acceptable excipient. The
25 proportion and nature of any acceptable excipient(s) are determined by the properties of the selected compound of the invention, the chosen route of administration, and standard practice as in the veterinary and pharmaceutical fields.

In one embodiment, the present invention provides compositions comprising: a compound
30 of invention and at least one acceptable excipient.

In effecting such treatment and/or control, a compound of the invention can be administered in any form and route which makes the compound bioavailable. The compounds of the invention can be administered by a variety of routes, including orally, in particularly by tablets and capsules. The compounds of the invention can be
5 administered parenteral routes, more particularly by inhalation, subcutaneously, intramuscularly, intravenously, intraarterially, transdermally, intranasally, rectally, vaginally, occularly, topically, sublingually, and buccally, intraperitoneally, intraadiposally, intrathecally and via local delivery for example by catheter or stent. One skilled in the art can readily select the proper form and route of administration
10 depending upon the particular characteristics of the compound selected, the disorder or condition to be treated, the stage of the disorder or condition, and other relevant circumstances. The pharmaceutical compositions of the invention may be administered to the subject, for example, in the form of tablets, including chewable tablets, capsules, cachets, papers, lozenges, wafers, elixirs, boli, ointments, transdermal patches, aerosols,
15 inhalants, suppositories, drenches, solutions, injections, and suspensions.

The term “acceptable excipient” refers to those excipients typically used in preparing veterinary and pharmaceutical compositions and should be pure and non-toxic in the amounts used. They generally are a solid, semi-solid, or liquid material which in the
20 aggregate can serve as a vehicle or medium for the active ingredient. Some examples of acceptable excipients are found in Remington’s Pharmaceutical Sciences and the Handbook of Pharmaceutical Excipients and include diluents, vehicles, carriers, ointment bases, binders, disintegrates, lubricants, glidants, sweetening agents, flavoring agents, gel bases, sustained release matrices, stabilizing agents, preservatives, solvents, suspending
25 agents, buffers, emulsifiers, dyes, propellants, coating agents, and others.

In one embodiment, the composition is adapted for oral administration, such as a tablet or a capsule or a liquid formulation, for example, a solution or suspension, adapted for oral administration. In one embodiment, the composition is adapted for oral administration,
30 such as chewable formulation, adapted for oral administration. In still another embodiment, the composition is a liquid or semi-solid formulation, for example, a solution or suspension or a paste, adapted for parenteral administration.

In one embodiment, the composition is adapted for injection administration, such as a solution or suspension, adapted for injection administration.

5

Particular compositions for usage on subjects in the treatment and/or control of nematodes/ helminths comprise solutions; injectables; emulsions including classical emulsions, microemulsions and self-emulsifying compositions, that are waterless organic, preferably oily, compositions which form emulsions, together with body fluids, upon addition to the subject's body; suspensions (drenches); pour-on formulations; food additives; powders; tablets including effervescent tablets; boli; capsules including micro-capsules; and chewable treats. Particularly composition forms are tablets, capsules, food additives or chewable treats.

15 The compositions of the present invention are prepared in a manner well known in the veterinary and pharmaceutical art and include at least one of the compounds of the invention as the active ingredient. The amount of a compound of the present invention may be varied depending upon its particular form and may conveniently be between 1% to about 50% of the weight of the unit dose form. The present pharmaceutical
20 compositions are preferably formulated in a unit dose form, each dose typically containing from about 0.5 mg to about 100 mg of a compounds of the invention. One or more unit dose form(s) may be taken to affect the treatment dosage.

In one embodiment, the present invention also provides a method for treating pests,
25 comprising: administering to a subject in need thereof an effective amount of a compound of formula (I) or a salt thereof, the method optionally further comprising an effective amount of at least one additional active compound.

In one embodiment, the present invention also provides a method for controlling pests,
30 comprising: administering to a subject in need thereof an effective amount of a compound of formula (I) or a salt thereof, the method optionally further comprising an effective amount of at least one additional active compound.

In one embodiment, the present invention also provides a method for treating or controlling pests, comprising: contacting a subject's environment with an effective amount of a compound of formula (I) or a salt thereof, the method optionally further comprising an effective amount of at least one additional active compound.

Thus, the invention provides for the use of the compounds of the invention as a medicament, including for the manufacture of a medicament. In one embodiment, the invention provides the manufacture of a medicament comprising a compound of formula (I) or a salt thereof for treating pests. In one embodiment, the invention provides the manufacture of a medicament comprising a compound of the invention or a salt thereof for controlling pests.

The terms "treating", "to treat", "treated", or "treatment", include without limitation restraining, slowing, stopping, reducing, ameliorating, reversing the progression or severity of an existing symptom, or preventing a disorder, condition, or disease. For example, an adult heartworm infection would be treated by administering a compound of the invention. A treatment may be applied or administered therapeutically.

The terms "control", "controlling" or "controlled" refers to include without limitation decreasing, reducing, or ameliorating the risk of a symptom, disorder, condition, or disease, and protecting an animal from a symptom, disorder, condition, or disease. Controlling may refer to therapeutic, prophylactic, or preventative administration. For example, a larvae or immature pest may be asymptomatic but would be controlled by acting on the larvae or immature pest preventing the infection from progressing to a symptomatic or debilitating infection by mature pest.

Thus, the use of the compounds of the invention in the treatment and/or control of pests, in particular helminths, in which the endoparasitic nematodes and trematodes refers to the use of the compounds of the invention to act on the various forms of the pest throughout its life cycle, independent of whether a subject is manifesting a symptom, including morbidity or mortality, and independently of the phase(s) of the challenge.

As used herein, “administering to a subject” includes but is not limited to cutaneous, subcutaneous, intramuscular, mucosal, submucosal, transdermal, oral or intranasal administration. Administration could include injection or topical administration, for
5 example, pour-on or spot-on administration. The pour-on or spot-on method is especially advantageous for use on herd animals such as cattle, horses, sheep or pigs, in which it is difficult or time-consuming to treat all the animals orally or by injection. Because of its simplicity, this method can of course also be used for all other animals, including individual domestic animals or pets, and is greatly favoured by the keepers of the animals,
10 as it can often be carried out without the specialist presence of the veterinarian.

The terms “subject” and “patient” refers includes humans and non-human mammalian animals and fish, the vertebrates described herein, such as dogs, cats, mice, rats, guinea pigs, rabbits, ferrets, cows, horses, sheep, goats, and pigs. Particular subjects are mammalian pets or companion animals, such as dogs and cats and also mice, guinea pigs,
15 ferrets, and rabbits.

The term “effective amount” refers to an amount which gives the desired benefit to the subject and includes administration for both treatment and control. The amount will vary from one individual subject to another and will depend upon a number of factors,
20 including the overall physical condition of the subject and the severity of the underlying cause of the condition to be treated, concomitant treatments, and the amount of compound of the invention used to maintain desired response at a beneficial level.

An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under
25 analogous circumstances. In determining the effective amount, the dose, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of patient; its size, age, and general health; the specific condition, disorder, infection, or disease involved; the degree of or involvement or the severity of the condition, disorder, or disease, the response of the individual patient; the particular
30 compound administered; the mode of administration; the bioavailability characteristics of

the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances. An effective amount of the present invention, the treatment dosage, is expected to range from 0.5 mg to 100 mg. Specific amounts can be determined by the skilled person. Although these dosages are based on a
5 subject having a mass of about 1 kg to about 20 kg, the diagnostician will be able to determine the appropriate dose for a subject whose mass falls outside of this weight range. An effective amount of the present invention, the treatment dosage, is expected to range from 0.1 mg to 10 mg/kg of the subject. The dosing regimen is expected to be monthly, quarterly, semi-annual, or annual administration.

10

The compounds of the invention may be combined with one or more other active compounds or therapies for the treatment of one or more disorders, diseases or conditions, including the treatment of pests, for which it is indicated. The compounds of the invention may be administered simultaneously, sequentially or separately in combination with one
15 or more compounds or therapies for treating pests and other disorders.

20

Thus, it is understood that the compositions and methods of the present invention optionally include comprising an effective amount of at least one additional active compound. Additional active compounds useful in the present invention include those
20 used to treat fleas, ticks, flies, and mosquitos and include macrocyclic lactones, like milbemycin oxime, imidacloprid, spinosad, pyriproxyfen, permethrin, S-methoprene, praziquantel and moxidectin. Further exemplary addition active compounds include, but are not limited to, afoxolaner, broflanimide, fluralaner, fluxametamide, isocycloseram, lotilaner, modoflaner, nicofluprole, sarolaner, tigolaner, albendazole, cambendazole,
25 fenbendazole, flubendazole, mebendazole, oxfendazole, parabendazole, tiabendazole, triclofenbendazole, amitraz, demiditraz, clorsulon, closantel, oxyclozanide, rafoxanide, cyphenothrin, deltamethrin, flumethrin, permethrin, cyromazine, derquantel, diamphenetide, dicyclanil, dinotefuran, imidacloprid, nitenpyram, thiamethoxam, abamectin, doramectin, emamectin, eprinomectin, ivermectin, moxidectin, selamectin,
30 milbemycin oxime, emodepside, epsiprantel, fipronil, fluazuron, fluhexafon, indoxacarb, levamisole, lufenuron, metaflumizone, methoprene, monepantel, morantel, niclosamide, nitroscanate, nitroxylin, novaluron, oxantel, praziquantel, pyrantel, pyriprole,

pyriproxyfen, sisapronil, spinosad, spinetoram and triflumezopyrim, or a salt of any of the foregoing.

- 5 The activity of the compounds of the invention may be determined by a variety of methods, including in vitro and in vivo methods.

Example A

In vitro evaluation of ingestion activity against adult cat fleas

- 10 To prepare the test blood mixture for feeding fleas, the test substance is dissolved in dimethyl sulphoxide and diluted with citrated cattle blood to the desired concentration. To assemble the test set-up, about 20 unfed adult male and female cat fleas (*Ctenocephalides felis*) are placed into a chamber which is closed at the top and bottom with gauze. A metal cylinder is sealed at one end with parafilm membrane, placed with the sealed base onto the
- 15 chamber, and filled with the test blood mixture, which can be imbibed by the fleas through the parafilm membrane. The blood cylinder part of the assembled test set-up is contained at about 37 °C in an isolated air heated container above the isolating carrier plate holding the flea chambers. The flea chamber part is kept at room temperature. After 48 hours, the insecticidal activity against fleas is determined. 100% means that all of the fleas have been
- 20 killed or rendered moribund; 0% means that none of the fleas have been affected at the dose administered. From a dose response curve the respective EC₅₀ was calculated (4-parameter logistic curve fitting). A substance shows good insecticidal activity against *Ctenocephalides felis* if the EC₅₀ is below an application rate of 20 ppm.

- In this test for example, the following compounds from the preparation examples showed
- 25 EC₅₀ < 1 ppm: Examples 1.5, 1.8, 1.9, 1.11, 1.13, 1.14, 2.3, and 3.1.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 5 ppm: Examples 1.1, 1.5, 1.8, 1.9, 1.11, 1.13, 1.14, 2.3, 2.4, and 3.1.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 20 ppm: Examples 1.1, 1.3, 1.4, 1.5, 1.8, 1.9, 1.11, 1.13, 1.14, 2.3, 2.4, and 3.1.

- 30 For the data above, where single isomers were tested, without knowing the absolute configuration of the isomer, the data indicates that the test article is one isomer or another, for example, Example 1.1 or its enantiomer.

Example B

In vitro evaluation of contact activity against adult Brown Dog ticks

In vitro contact tests with ticks are conducted with adult males and females of
5 *Rhipicephalus sanguineus*. For the coating of the test vials, the test substance is dissolved
and diluted in acetone p.a. to the desired concentration. The solution is then homogeneously
applied to the inner walls and base of a glass vial by turning and rocking on an orbital
shaker until complete evaporation of the solvent. For example, with 900 ppm solution of
test substance an area-based dose of 5 $\mu\text{g}/\text{cm}^2$ is achieved. After the solvent is completely
10 evaporated, 5 -10 adult ticks are applied to each coated test vial, which is then sealed with
a perforated plastic lid and incubated in a horizontal position in the dark at room
temperature and ambient humidity. Acaricidal activity is determined after 48 h. For this,
ticks are moved to the base of the test vial by gentle knocking, and test vials are then
incubated on a hotplate at 45-50°C for no longer than 5 min. Ticks which remain motionless
15 on the base of the test vial or move uncoordinated without deliberately climbing up to avoid
the heat are considered dead or moribund, respectively. An acaricidal activity of 100%
means all ticks were dead or moribund. An acaricidal activity of 0% means none of the
ticks was found dead or moribund. From a dose response curve the respective EC₅₀ was
calculated (4-parameter logistic curve fitting). A substance shows good acaricidal activity
20 against *Rhipicephalus sanguineus* if the EC₅₀ is below an application rate of 5 $\mu\text{g}/\text{cm}^2$.
In this test for example, the following compounds from the preparation examples showed
EC₅₀ < 0.04 $\mu\text{g}/\text{cm}^2$: Examples 1.3, 1.5, 1.8. and 3.1.
In this test for example, the following compounds from the preparation examples showed
EC₅₀ < 0.25 $\mu\text{g}/\text{cm}^2$: Examples 1.1, 1.3, 1.4, 1.5, 1.8 and 3.1.
25 In this test for example, the following compounds from the preparation examples showed
EC₅₀ < 1 $\mu\text{g}/\text{cm}^2$: Examples 1.1, 1.3, 1.4, 1.5, 1.8, 2.3 and 3.1.
For the data above, where single isomers were tested, without knowing the absolute
configuration of the isomer, the data indicates that the test article is one isomer or another,
for example, Example 1.1 or its enantiomer.

30

Example C

In vitro evaluation of contact activity against adult Cat fleas

In vitro contact tests with ticks are conducted with adult males and females of *Ctenocephalides felis*. For the coating of the test vials, the test substance is dissolved and diluted in acetone p.a. to the desired concentration. The solution is then homogeneously applied to the inner walls and base of a glass vial by turning and rocking on an orbital shaker until complete evaporation of the solvent. For example, with 900 ppm solution of test substance an area-based dose of 5 µg/cm² is achieved.

After the solvent is completely evaporated, approximately 10 adult fleas are applied to each coated test vial, which is then sealed with a perforated plastic lid and incubated in a horizontal position in the dark at room temperature and ambient humidity. Insecticidal activity is determined after 48 h. Fleas which remain motionless on the base of the test vial or move uncoordinated without occasionally jumping or walking straight are considered dead or moribund, respectively. An insecticidal activity of 100% means all fleas were dead or moribund. An insecticidal activity of 0% means none of the fleas was affected. From a dose response curve the respective EC₅₀ was calculated (4-parameter logistic curve fitting). A substance shows good insecticidal activity against *Ctenocephalides felis* if the EC₅₀ is below an application rate of 5 µg/cm².

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 0.05 µg/cm²: Examples 3.1.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 0.1 µg/cm²: Examples 1.1, 1.3, 1.4, 1.8 and 3.1.

For the data above, where single isomers were tested, without knowing the absolute configuration of the isomer, the data indicates that the test article is one isomer or another, for example, Example 1.1 or its enantiomer.

Example D

In vitro evaluation of systemic activity against female engorged Cattle ticks

To prepare the test compound mixture for injecting ticks, the test substance is dissolved in dimethyl sulphoxide and diluted with the same solvent to the desired concentration. 1 µl of the test mixture is injected into each abdomen of 5 engorged adult female cattle ticks (*Rhipicephalus (Boophilus) microplus*). The ticks are individually transferred into the single

compartments of 5x5 replica plates and kept in a climate-controlled chamber (28°C, 85% rel. hum.). Acaricidal activity against cattle ticks is assessed after 7 days by assessment of laid fertile eggs. Eggs which do not appear normal may be stored in a climate-controlled cabinet [28°C, 85% rel h.] until larval hatch after 42 days. An acaricidal activity of 100% means that none of the ticks has laid eggs or laid eggs were infertile; 0% means that all the eggs are fertile. From a dose response curve the respective EC₅₀ was calculated (4-parameter logistic curve fitting). A substance shows good systemic acaricidal activity against *Rhipicephalus microplus* if the EC₅₀ is below an application rate of 10 µg/tick.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 1 µg/tick: Examples 1.5, 1.8, 2.3, and 3.1.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 2 µg/tick: Examples 1.1, 1.3, 1.5, 1.8, 2.3, 2.4, and 3.1.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 10 µg/tick: Examples 1.1, 1.3, 1.5, 1.8, 2.1, 2.2, 2.3, 2.4, and 3.1.

For the data above, where single isomers were tested, without knowing the absolute configuration of the isomer, the data indicates that the test article is one isomer or another, for example, Example 1.1 or its enantiomer.

Example E

In vitro evaluation of contact activity against larval cattle ticks

This *In vitro* contact tests are conducted with with larvae of *Rhipicephalus microplus*. For the coating of the test vials, the test substance is dissolved and diluted in acetone p.a. to the desired concentration. The solution is then homogeneously applied to the inner walls and base of a glass vial by turning and rocking on an orbital shaker until complete evaporation of the solvent. For example, with 900 ppm solution of test substance an area-based dose of 5 µg/cm² is achieved. After the solvent is completely evaporated, 10-20 larval ticks are applied to each coated test vial, which is then sealed with a perforated plastic lid and incubated in a horizontal position in trays that are kept in a climate-controlled chamber (28°C, 85% rel. hum.). Acaricidal activity is determined after 48 h. For this, vials are placed vertically and the natural negative egeotactic behavior of cattel tick larvaer is used to evaluate the effects.. Tick larvae which remain motionless on the base of the test vial or move uncoordinated without deliberately climbing up are considered dead or moribund,

respectively. An acaricidal activity of 100% means all tick larvae were dead or moribund. An acaricidal activity of 0% means none of the tick larvae was affected. From a dose response curve the respective EC₅₀ was calculated (4-parameter logistic curve fitting). A substance shows good acaricidal activity against *Rhipicephalus sanguineus* if the EC₅₀ is
5 below an application rate of 5 µg/cm².


In this test for example, the following compounds from the preparation examples showed EC₅₀ < 0.01 µg/cm²: Examples 1.3, 1.5, and 3.1.

In this test for example, the following compounds from the preparation examples showed EC₅₀ < 0.1 µg/cm²: Examples 1.1, 1.3, 1.4, 1.5, 2.3, and 3.1.

- 10 For the data above, where single isomers were tested, without knowing the absolute configuration of the isomer, the data indicates that the test article is one isomer or another, for example, Example 1.1 or its enantiomer.

WE CLAIM:

1. A compound of formula (I):



5 wherein

A₁ is selected from the group consisting of CF₃, CHF₂, CH₂F, and CF₂CF₃;

A₂ is O or S;

R₁ is selected from the group consisting of hydrogen and halogen;

10 R₂ is selected from the group consisting of hydrogen, halogen, difluoromethyl, and trifluoromethyl;

R₃ is selected from the group consisting of hydrogen, halogen, and trifluoromethyl;

R₄ is selected from the group consisting of hydrogen, halogen, difluoromethyl, and trifluoromethyl;

15 R₅ is selected from the group consisting of hydrogen and halogen; provided that:

R₁ may be hydrogen only when R₂ is trifluoromethyl, difluoromethyl, or bromo;


R₅ may be hydrogen only when R₄ is trifluoromethyl or bromo;

20 R₃ may be hydrogen only when one of R₂ or R₄ is either trifluoromethyl, difluoromethyl, or bromo;

R₁, R₃, and R₅ cannot all be hydrogen when R₂ and R₄ are trifluoromethyl; and

at most three of R₁, R₂, R₃, R₄, and R₅ are hydrogen;

25 Q is selected from the group consisting of



wherein

p is 0, 1, or 2;

q is 0, 1, 2, or 3;

5 r is 0 or 1;

s is 0, 1, or 2;

t is 0 or 1;

R₆, at each occurrence, is independently selected from the group consisting of halogen; cyano; nitro; hydroxyl; -NH₂; -NH(C₁-C₄ alkyl); -N(C₁-C₄ alkyl)₂; C₂-C₅-alkoxycarbonyl; C₁-C₆-alkyl optionally substituted with 1 to 5 substituents independently
 10 selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl; C₁-C₆-alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of
 15 halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇

aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl; -NR₈C(O)(C₁-C₄ alkyl) optionally substituted on the C₁-C₄ alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂, wherein R₈ is independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; -C(O)NR₈(C₁-C₄ alkyl) optionally substituted on the C₁-C₄ alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂, wherein R₈ is independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; -SC₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂; and -S(O)C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), and -N(C₁-C₄ alkyl)₂;

R₇, at each occurrence, is independently selected from the group consisting of oxo, C₁-C₄ alkyl, and C₃-C₆ cycloalkyl;

A₃ is O or S;

20 A₄ is CH or N;

A₅ is CH or N;

A₆ is CH or N;

A₇ is CH O, S, a bond, or N;

A₈ is CH O, S, a bond, or N;

25 A₉ is CH or N;

A₁₀ is CH or N;

A₁₁ is CH or N;

A₁₂ is CH or N;

A₁₃ is CH or N;

30 A₁₄ is CH or N;

A₁₅ is CH or N;

A₁₆ is NR, O, or S, wherein R is selected from the group consisting of hydrogen, C₁-C₄ alkyl, and C₃-C₆ cycloalkyl;

W₁ is selected from the group consisting of -O-, -S-, -NR₉-, -NC(O)R₁₀-, -CH₂-, and -C(O)-;

5 W₂ is selected from the group consisting of -O-, -S-, -NR₉-, -NC(O)R₁₀-, -CH₂-, and -C(O)-;

provided that:

when W₁ is -O-, -S-, -NR₉-, or -NC(O)R₁₀- then W₂ is -CH₂- or -C(O)-;
and

10 when W₂ is -O-, -S-, -NR₉-, or -NC(O)R₁₀- then W₁ is -CH₂- or -C(O)-;

W₃ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

W₄ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

15 W₅ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

W₆ is selected from the group consisting of nil, -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, -CH-, -N-, -CH₂-, and -C(O)-;

wherein the bonds between W₁, W₂, W₃, and W₄ may be single or double bonds;

20 provided that:

- (i) not more than two of W₁, W₂, W₃, and W₄ are nil;
- (ii) not more than two of W₁, W₂, W₃, and W₄ are -O-, -S-, -S(O)-, -S(O)₂-, -NR₉-, or -C(O)-;
- (iii) if two of W₁, W₂, W₃, and W₄ are -O- and/or -S- then at least one
25 carbon atom is present between them; and
- (iv) when W₁, W₂, W₃, or W₄ is -CH- and/or -NR₉- then a double bond is
formed within the ring formed by W₁, W₂, W₃, and W₄;

R₉, at each occurrence, is independently selected from the group consisting of hydrogen and C₁-C₆-alkyl optionally substituted with 1 to 5 substituents independently
30 selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl;


R₁₀, at each occurrence, is independently selected from the group consisting of oxo, C₁-C₄ alkyl, and C₃-C₆ cycloalkyl;

X is 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N,

5 wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of
10 halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl,

15 wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, and C₃-C₆ cycloalkyl;
20 or

X is selected from the group consisting of



25 wherein

R₁₁ is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₂-C₇ alkylcarbonyl, C₂-C₅ alkoxy carbonyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl;

W is selected from the group consisting of

(i) hydrogen;

(ii) C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently

- 5 selected from the group consisting of halogen; cyano; hydroxyl; oxo; C₁-C₄ alkoxy; C₃-C₆ cycloalkyl optionally substituted by 1 to 3 substituents independently selected from the group halogen and cyano; acetylenyl; -NH₂; C₁-C₇ aminocarbonyl; -NH(C₁-C₄ alkyl); -N(C₁-C₄ alkyl)₂; -SC₁-C₄ alkyl; -S(O)C₁-C₄ alkyl; -SO₂C₁-C₄ alkyl; -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, and -NH₂; -C(O)NH-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, and -NH₂; -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen; -C(O)NH-C₁-C₆ haloalkyl; -C(O)-4- to 7-membered heterocycloalkyl attached by a nitrogen and optionally having 1 or 2 other heteroatoms selected from the group O, S, and N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH₂, C₁-C₇ aminocarbonyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any other N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl; 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are

optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any S in the heteroaryl is optionally substituted with 1 or 2 oxygen atom(s); phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl; C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C₁-C₄ haloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl; and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, B, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, wherein any B in the of the 4- to 7-membered

heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with hydroxyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of

- 5 hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, -C(O)-NH₂, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, 5- to 10 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s);

- 15 (iii) C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, carboxyl, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C₁-C₄ haloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, C₂-C₆ alkenyl optionally substituted with 1 to 3 halogens, and C₂-C₆ alkynyl;

- (iv) 6-membered aryl or 5- to 10-membered heteroaryl having 1, 2 or 3 heteroatoms selected from the group O, S, and N, wherein the carbons of the 6-membered aryl and the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 25 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and 30 -C(O)NH-C₃-C₆ cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen,

and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl;

- 5 (v) 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)₂, -C(O)-NH₂, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s); and

(vi) -NR₁₂R₁₃

wherein

- R₁₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₁-C₇ alkylcarbonyl, C₁-C₇ aminocarbonyl, and C₂-C₅ alkoxycarbonyl;

R_{13} is selected from the group consisting of hydrogen, C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and
 5 -SO₂C₁-C₄ alkyl, C₃-C₆ cycloalkyl, -C(O)-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl, 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected
 10 from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the
 15 group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, and C₃-C₆ cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency
 20 permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆
 25 cycloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s); and 5- to 10-membered heteroaryl having 1 or 2 heteroatoms
 30 selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally

substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

or

R₁₁ and W are taken together with the nitrogen to which they are attached to form a 4- to 7-membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S, and O, wherein the carbons of the ring are optionally substituted with 1 to 4 substituents independently selected of cyano, hydroxyl, oxo, halogen, C₁-C₂ alkoxy, N,N-di-C₁-C₄-alkylaminocarboxyl, N-C₁-C₄-alkylaminocarboxyl, C₁-C₇ aminocarboxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, cyano, hydroxyl, and C₁-C₄ alkoxy, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, hydroxyl, C₁-C₂ alkoxy, N,N-di-C₁-C₄-alkylaminocarboxyl, N-C₁-C₄-alkylaminocarboxyl, and C₁-C₇ aminocarboxyl, wherein any N in the 4- to 7-membered ring is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, C₃-

C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered ring is optionally substituted with 1 or 2 oxygen atom(s); and

Y is C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, acetylenyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)₂, -SO₂NH(C₁-C₄ haloalkyl), -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, and -NH₂, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen, -C(O)NH-C₁-C₆ haloalkyl, phenyl optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, and C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl, 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆

cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, wherein any N in the heteroaryl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents

5 independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the

10 heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano,

15 hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the

20 group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and 5- to 6-membered heteroaryl, wherein any S in the 4- to 7-

25 membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s);

or a salt thereof.

2. A compound according to claim 1, wherein

30 W is selected from the group consisting of

(i) hydrogen;

(ii) C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen; cyano; hydroxyl; oxo; C₁-C₄ alkoxy; C₃-C₆ cycloalkyl optionally substituted by 1 to 3 substituents independently selected from the group halogen and cyano; acetylenyl; -NH₂; C₁-C₇ aminocarbonyl; -NH(C₁-C₄ alkyl); -N(C₁-C₄ alkyl)₂; -SC₁-C₄ alkyl; -S(O)C₁-C₄ alkyl; -SO₂C₁-C₄ alkyl; -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, and -NH₂; -C(O)NH-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, and -NH₂; -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen; -C(O)NH-C₁-C₆ haloalkyl; -C(O)-4- to 7-membered heterocycloalkyl attached by a nitrogen and optionally having 1 or 2 other heteroatoms selected from the group O, S, and N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH₂, C₁-C₇ aminocarbonyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any other N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl; 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano,

hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any S in the heteroaryl is optionally substituted with 1 or 2 oxygen atom(s); phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl; C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C₁-C₄ haloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl; and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, B, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, and C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, wherein any B in the of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with hydroxyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency

permitting, is substituted with a substituent selected from the group consisting of
 hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, -C(O)-
 NH₂, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected
 from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄
 5 alkoxy, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄
 alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, 5- to
 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents
 independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and
 hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-
 10 fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen
 atom(s);

(iii) C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently
 selected from the group consisting of halogen, cyano, hydroxyl, oxo, carboxyl, C₁-C₄
 alkoxy, C₁-C₄ alkyl optionally substituted with 1 to 3 groups selected from the group
 15 consisting of halogen and cyano, C₁-C₄ haloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄
 alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-
 C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, C₂-C₆ alkenyl optionally
 substituted with 1 to 3 halogens, and C₂-C₆ alkynyl;

(iv) 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the
 20 group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are
 optionally substituted with 1, 2 or 3 substituents independently selected from the group
 consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to
 5 substituents independently selected from the group consisting of halogen, cyano,
 hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄
 25 alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl,
 and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -
 NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, wherein any N
 in the heteroaryl, valency permitting, is optionally substituted with a substituent selected
 from the group consisting of hydrogen, and C₁-C₄ alkyl optionally substituted with 1 to 5
 30 substituents independently selected from the group consisting of halogen, cyano,
 hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄

alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl;

(v) 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-C₁-C₆ haloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, -NH₂, C₁-C₇ aminocarbonyl, -SO₂C₁-C₄ alkyl, -SO₂C₁-C₄ haloalkyl, -C(O)-NH₂, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, C₃-C₆ cycloalkyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s); and

(vi) -NR₁₂R₁₃

wherein

R₁₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₄-C₇ alkylcycloalkyl, C₁-C₇ alkylcarbonyl, C₁-C₇ aminocarbonyl, and C₂-C₅ alkoxycarbonyl;

R₁₃ is selected from the group consisting of hydrogen, C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇

aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl, C₃-C₆ cycloalkyl, -C(O)-C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇

5 aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, and -SO₂C₁-C₄ alkyl, 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents

10 independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, and -C(O)NH-

15 C₁-C₆ haloalkyl, and C₃-C₆ cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or

20 optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s); and 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of

30 halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-

C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen,
 5 C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl;

10 or

R₁₁ and W are taken together with the nitrogen to which they are attached to form a 4- to 7-membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S, and O, wherein the carbons of the ring are optionally substituted with 1 to 4 substituents independently selected of cyano, hydroxyl, oxo, halogen, C₁-C₂
 15 alkoxy, N,N-di-C₁-C₄-alkylaminocarboxyl, N-C₁-C₄-alkylaminocarboxyl, C₁-C₇ aminocarboxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents selected
 20 from the group consisting of halogen, cyano, hydroxyl, and C₁-C₄ alkoxy, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ haloalkyl, 5- to 6-membered heteroaryl, and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, hydroxyl, C₁-C₂ alkoxy, N,N-di-C₁-C₄-alkylaminocarboxyl, N-C₁-C₄-alkylaminocarboxyl, and C₁-C₇
 25 aminocarboxyl, wherein any N in the 4- to 7-membered ring is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, C₃-
 30 C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, 5- to 6-membered heteroaryl, and phenyl

optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, cyano, and hydroxyl, wherein any S in the 4- to 7-membered ring is optionally substituted with 1 or 2 oxygen atom(s); and

Y is C₁-C₆ alkyl optionally substituted with 1 to 5 substituents independently
 5 selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₃-C₆ cycloalkyl, C₁-C₄ alkoxy, acetylenyl, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C₁-C₄ alkyl optionally substituted with 1 to 5
 10 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C₁-C₄ alkoxy, and -NH₂, -C(O)NH-C₁-C₆ alkyl, -C(O)NH-C₁-C₆ cyanoalkyl optionally substituted with 1 to 3 halogen, -C(O)NH-C₁-C₆ haloalkyl, phenyl optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 3 substituents
 15 independently selected from the group consisting of halogen, cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, and -C(O)NH-C₃-C₆ cycloalkyl, and C₃-C₆ cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄
 20 alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, -C(O)NH-C₁-C₆ alkyl, C₂-C₆ alkenyl, and C₂-C₆ alkynyl, 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro,
 25 hydroxyl, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl),
 30 -N(C₁-C₄ alkyl)₂, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, wherein any N in the heteroaryl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents

independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group O, S, and N, wherein the heterocycloalkyl is optionally benzo-fused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, and C₃-C₆ cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with a substituent selected from the group consisting of hydrogen, C₁-C₄ alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C₁-C₄ alkoxy, -NH₂, C₁-C₇ aminocarbonyl, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -SC₁-C₄ alkyl, -S(O)C₁-C₄ alkyl, -SO₂C₁-C₄ alkyl, -C(O)NH-C₃-C₆ cycloalkyl, and -C(O)NH-C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and 5- to 6-membered heteroaryl, wherein any S in the 4- to 7-membered heterocycloalkyl or optionally benzo-fused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atom(s);
or a salt thereof.

3. A compound according to claim 1 wherein A₁ is trifluoromethyl, A₂ is O, R₁ is hydrogen, R₂ is trifluoromethyl, R₃ is hydrogen, R₄ is trifluoromethyl or halogen, and R₅ is halogen; or a salt thereof.

4. A compound according to claim 3 wherein R₄ is halogen; or a salt thereof.

30

5. A compound according to claim 3 wherein R₄ is trifluoromethyl; or a salt thereof.

6. A compound according to claim 4 wherein R₄ is chloro or bromo; or a salt thereof.

5 7. A compound according to claim 4 wherein R₄ is bromo; or a salt thereof.

8. A compound according to claim 4 wherein R₄ is chloro; or a salt thereof.

9. A compound according to any of claims 1–8 wherein R₅ is fluoro; or a salt thereof.

10

10. A compound according to claim 1, selected from the group consisting of:

4-(rel-(*S*)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-((*S*)-1-ethyl-5-oxopyrrolidin-3-yl)-2-methylbenzamide

4-(rel-(*S*)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(*S*)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide

4-(rel-(*S*)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(*R*)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide

cis-3-(4-((*S*^{*})-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzamido)cyclobutane-1-carboxylic acid

trans-3-(4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzamido)cyclobutane-1-carboxylic acid

4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(*cis*-3-(methylcarbamoyl)cyclobutyl)benzamide

4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(*trans*-3-(methylcarbamoyl)cyclobutyl)benzamide

rel-(S)-4-(5-(2-fluoro-3,5-bis(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)benzamide

4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((*trans*)-3-(trifluoromethyl)cyclobutyl)benzamide

4-(rel-(R)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(S)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide

4-(rel-(R)-5-(3-bromo-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-(rel-(R)-2-(methylsulfonyl)isoxazolidin-4-yl)benzamide

4-((S*)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((cis)-3-(trifluoromethyl)cyclobutyl)benzamide

rel-4-((R)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((S*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide

rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((S*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide

rel-4-((R)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((R*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide

rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((R*)-3-(2,2,2-trifluoroethyl)-4,5-dihydroisoxazol-5-yl)benzamide

rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((R*)-2-(2,2,2-trifluoroethyl)isoxazolidin-4-yl)benzamide

rel-4-((S)-5-(3-chloro-2-fluoro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methyl-N-((S)-2-(2,2,2-trifluoroethyl)isoxazolidin-4-yl)benzamide

or a salt of any of the foregoing.

11. A composition comprising a compound of any one of claims 1 to 10, or a salt thereof, and at least one acceptable carrier.

12. The use of a compound of any one of claims 1 to 10, or a salt thereof, as a medicament.

13. The use of a compound of any one of claims 1 to 10, or a salt thereof, in the manufacture of a medicament for treating pests.

14. The use of a compound of any one of claims 1 to 10, or a salt thereof, in the manufacture of a medicament for treating fleas.

15. The use of a compound of any one of claims 1 to 10, or a salt thereof, in the manufacture of a medicament for controlling ticks.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2022/066422

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D261/04 C07D413/12 A01N43/80
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 2021/127188 A1 (ELANCO TIERGESUNDHEIT AG [CH]; ELANCO US INC [US]) 24 June 2021 (2021-06-24) cited in the application claim 1 -----	1-15
X	EP 1 731 512 A1 (NISSAN CHEMICAL IND LTD [JP]) 13 December 2006 (2006-12-13) cited in the application claims 1,9 -----	1-15
X	WO 2012/120399 A1 (PFIZER [US]; BILLEN DENIS [US] ET AL.) 13 September 2012 (2012-09-13) cited in the application claim 1 -----	1-15
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 August 2022

Date of mailing of the international search report

31/08/2022

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Gettins, Marc

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2022/066422

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/112275 A1 (BAYER CROPSCIENCE AG [DE]; MURATA TETSUYA [JP] ET AL.) 17 September 2009 (2009-09-17) cited in the application claim 1 -----	1-15
X	WO 2010/070068 A2 (NOVARTIS AG [CH]; NANCHEN STEVE [CH] ET AL.) 24 June 2010 (2010-06-24) cited in the application claim 1 -----	1-15
X	WO 2007/079162 A1 (DU PONT [US]; LAHM GEORGE PHILIP [US] ET AL.) 12 July 2007 (2007-07-12) cited in the application claim 1 -----	1-15
X	WO 2009/002809 A2 (DU PONT [US]; LAHM GEORGE PHILIP [US] ET AL.) 31 December 2008 (2008-12-31) cited in the application claims 1,20 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/066422

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2021127188	A1	24-06-2021	AR	120804	A1	16-03-2022
			AU	2020408351	A1	11-08-2022
			CA	3164924	A1	24-06-2021
			US	2021188789	A1	24-06-2021
			WO	2021127188	A1	24-06-2021

EP 1731512	A1	13-12-2006	AU	2005219788	A1	15-09-2005
			AU	2010212450	A1	09-09-2010
			BR	PI0508140	A	24-07-2007
			CA	2558848	A1	15-09-2005
			CN	1930136	A	14-03-2007
			CN	101768129	A	07-07-2010
			CN	102532048	A	04-07-2012
			CN	102558082	A	11-07-2012
			CY	1115818	T1	14-12-2016
			DK	1731512	T3	05-01-2015
			EA	200601639	A1	27-02-2007
			EA	200900197	A1	30-06-2009
			EP	1731512	A1	13-12-2006
			ES	2526614	T3	13-01-2015
			HR	P20141241	T1	13-02-2015
			HU	S1500009	I1	28-06-2017
			IL	177949	A	28-02-2013
			JP	4883296	B2	22-02-2012
			JP	5321856	B2	23-10-2013
			JP	2012006944	A	12-01-2012
			JP	WO2005085216	A1	17-01-2008
			KR	20070010145	A	22-01-2007
			KR	20110132638	A	08-12-2011
			LU	92672	I2	02-11-2015
			NL	300721	I1	29-12-2015
			PL	1731512	T3	31-03-2015
			PT	1731512	E	24-11-2014
			SI	1731512	T1	30-01-2015
			TW	I355896	B	11-01-2012
			US	2007066617	A1	22-03-2007
			US	2009312330	A1	17-12-2009
			US	2011251398	A1	13-10-2011
			US	2012172615	A1	05-07-2012
			US	2013296559	A1	07-11-2013
			US	2015105398	A1	16-04-2015
			US	2017065565	A1	09-03-2017
			US	2018318266	A1	08-11-2018
			US	2020000777	A1	02-01-2020
			US	2020155511	A1	21-05-2020
			WO	2005085216	A1	15-09-2005
			ZA	200607637	B	28-05-2008

WO 2012120399	A1	13-09-2012	AR	085649	A1	16-10-2013
			AU	2012226475	A1	12-09-2013
			BR	112013023068	A2	26-07-2016
			CA	2828397	A1	13-09-2012
			CL	2013002516	A1	13-06-2014
			CN	103517907	A	15-01-2014
			CO	6761337	A2	30-09-2013
			CY	1117987	T1	17-05-2017
			EP	2683723	A1	15-01-2014
			ES	2585555	T3	06-10-2016

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/066422

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		HK 1190393 A1	04-07-2014
		HR P20160601 T1	01-07-2016
		HU E029810 T2	28-03-2017
		JP 5806743 B2	10-11-2015
		JP 2014508773 A	10-04-2014
		KR 20140017590 A	11-02-2014
		ME 02412 B	20-09-2016
		NZ 614547 A	24-12-2014
		PL 2683723 T3	31-07-2017
		PT 2683723 T	05-08-2016
		RU 2013139630 A	20-04-2015
		US 2012232026 A1	13-09-2012
		UY 33943 A	31-10-2012
		WO 2012120399 A1	13-09-2012
		ZA 201306817 B	27-07-2016
WO 2009112275 A1	17-09-2009	AR 070866 A1	12-05-2010
		AU 2009224896 A1	17-09-2009
		BR PI0909504 A2	04-08-2015
		CA 2718199 A1	17-09-2009
		CL 2009000509 A1	13-08-2010
		CN 101970403 A	09-02-2011
		CO 6321194 A2	20-09-2011
		CR 11672 A	24-02-2011
		DO P2010000271 A	15-10-2010
		EP 2254863 A1	01-12-2010
		JP 2009286773 A	10-12-2009
		JP 2011517663 A	16-06-2011
		KR 20100138987 A	31-12-2010
		KR 20130100387 A	10-09-2013
		NI 201000151 A	23-03-2011
		PE 20091619 A1	05-11-2009
		SV 2010003661 A	14-01-2011
		TW 200950703 A	16-12-2009
		US 2011071141 A1	24-03-2011
		UY 31690 A	10-11-2009
		WO 2009112275 A1	17-09-2009
		ZA 201006502 B	30-11-2011
WO 2010070068 A2	24-06-2010	AR 074790 A1	09-02-2011
		AU 2009327079 A1	24-06-2010
		BR PI0923009 A2	11-08-2015
		CA 2747354 A1	24-06-2010
		CL 2011001390 A1	28-10-2011
		CN 102256971 A	23-11-2011
		CO 6341475 A2	21-11-2011
		DK 2379537 T3	17-12-2012
		EP 2379537 A2	26-10-2011
		ES 2395704 T3	14-02-2013
		HU S1700034 I1	28-09-2017
		JP 5608676 B2	15-10-2014
		JP 2012512838 A	07-06-2012
		LU C00030 I1	10-08-2017
		NO 2017048 I1	08-09-2017
		NZ 593135 A	26-04-2013
		PL 2379537 T3	29-03-2013
		PT 2379537 E	27-12-2012
		TW 201024289 A	01-07-2010

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/066422

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2011245239 A1	06-10-2011
		US 2013131053 A1	23-05-2013
		US 2014120147 A1	01-05-2014
		WO 2010070068 A2	24-06-2010
		ZA 201103780 B	25-01-2012
WO 2007079162 A1	12-07-2007	AR 058896 A1	27-02-2008
		AT 496900 T	15-02-2011
		AU 2006332749 A1	12-07-2007
		BR PI0621171 A2	29-11-2011
		CA 2632694 A1	12-07-2007
		CN 101351456 A	21-01-2009
		CY 1111736 T1	07-10-2015
		DK 1973888 T3	16-05-2011
		EP 1973888 A1	01-10-2008
		ES 2358683 T3	12-05-2011
		HR P20110223 T1	30-06-2011
		HU S1400043 I1	28-08-2017
		IL 191512 A	30-07-2015
		JO 2668 B1	17-06-2012
		JP 5242413 B2	24-07-2013
		JP 2009522282 A	11-06-2009
		KR 20080094015 A	22-10-2008
		KR 20120013453 A	14-02-2012
		LU 92512 I2	06-10-2014
		MA 30070 B1	01-12-2008
		MD 20080171 A	31-07-2009
		ME 00496 B	10-10-2011
		MY 149421 A	30-08-2013
		MY 169840 A	16-05-2019
		NZ 568026 A	29-10-2010
		PL 1973888 T3	30-06-2011
		PT 1973888 E	22-02-2011
		RS 51670 B	31-10-2011
		RS 20060699 A	07-08-2008
		SI 1973888 T1	30-06-2011
		TW I412322 B	21-10-2013
		US 2010234219 A1	16-09-2010
		US 2011263641 A1	27-10-2011
		US 2013029845 A1	31-01-2013
		US 2014038821 A1	06-02-2014
		US 2014249314 A1	04-09-2014
		UY 30069 A1	31-07-2007
		WO 2007079162 A1	12-07-2007
		ZA 200804384 B	26-08-2009
WO 2009002809 A2	31-12-2008	AR 067185 A1	30-09-2009
		AR 110434 A2	27-03-2019
		AU 2008268614 A1	31-12-2008
		BR PI0810936 A2	23-12-2014
		BR 122018001898 B1	21-07-2020
		CA 2684632 A1	31-12-2008
		CL 2008001879 A1	22-05-2009
		CN 101765592 A	30-06-2010
		CY 1119101 T1	07-03-2018
		DK 2158188 T3	07-08-2017
		DK 3222618 T3	30-11-2020
		EP 2158188 A2	03-03-2010

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/066422

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 3222618 A1	27-09-2017
		ES 2633448 T3	21-09-2017
		ES 2836269 T3	24-06-2021
		GT 200900321 A	25-03-2011
		HR P20171018 T1	03-11-2017
		HR P20201897 T1	02-04-2021
		HU E035329 T2	02-05-2018
		HU E052554 T2	28-05-2021
		IL 201671 A	28-05-2014
		JP 5467042 B2	09-04-2014
		JP 2010531883 A	30-09-2010
		KR 20100021533 A	24-02-2010
		LT 2158188 T	10-07-2017
		LT 3222618 T	28-12-2020
		MA 31444 B1	01-06-2010
		ME 00967 B	20-06-2012
		MY 156005 A	31-12-2015
		MY 158669 A	31-10-2016
		NO 2017049 I1	14-09-2017
		NZ 580396 A	29-07-2011
		PL 2158188 T3	31-10-2017
		PL 3222618 T3	25-01-2021
		PT 2158188 T	28-07-2017
		PT 3222618 T	30-11-2020
		RU 2010102224 A	10-08-2011
		SI 2158188 T1	31-08-2017
		SI 3222618 T1	26-02-2021
		TN 2009000488 A1	31-03-2011
		TW 200906810 A	16-02-2009
		UA 99822 C2	10-10-2012
		US 2010254959 A1	07-10-2010
		US 2013217736 A1	22-08-2013
		UY 31177 A1	30-01-2009
		WO 2009002809 A2	31-12-2008